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ABSTRACT Haloperidol is an efficacious antipsychotic drug that has serious, unpredictable motor side effects that limit its utility and
cause noncompliance in many patients. Using a drug–placebo diallel of the eight founder strains of the Collaborative Cross and their F1
hybrids, we characterized aggregate effects of genetics, sex, parent of origin, and their combinations on haloperidol response. Treating
matched pairs of both sexes with drug or placebo, we measured changes in the following: open field activity, inclined screen rigidity,
orofacial movements, prepulse inhibition of the acoustic startle response, plasma and brain drug level measurements, and body
weight. To understand the genetic architecture of haloperidol response we introduce new statistical methodology linking heritable
variation with causal effect of drug treatment. Our new estimators, “difference of models” and “multiple-impute matched pairs”, are
motivated by the Neyman–Rubin potential outcomes framework and extend our existing Bayesian hierarchical model for the diallel
(Lenarcic et al. 2012). Drug-induced rigidity after chronic treatment was affected by mainly additive genetics and parent-of-origin
effects (accounting for 28% and 14.8% of the variance), with NZO/HILtJ and 129S1/SvlmJ contributions tending to increase this side
effect. Locomotor activity after acute treatment, by contrast, was more affected by strain-specific inbreeding (12.8%). In addition to
drug response phenotypes, we examined diallel effects on behavior before treatment and found not only effects of additive genetics
(10.2–53.2%) but also strong effects of epistasis (10.64–25.2%). In particular: prepulse inhibition showed additivity and epistasis in
about equal proportions (26.1% and 23.7%); there was evidence of nonreciprocal epistasis in pretreatment activity and rigidity; and
we estimated a range of effects on body weight that replicate those found in our previous work. Our results provide the first
quantitative description of the genetic architecture of haloperidol response in mice and indicate that additive, dominance-like in-
breeding and parent-of-origin effects contribute strongly to treatment effect heterogeneity for this drug.
DRUG treatment at its best can provide a simple solutionto a complex problem. It is well recognized that diseases
to which drug treatment is most commonly applied are af-
fected by a complex interaction between multiple heritable
and environmental factors; yet despite such interindividual
differences in etiology, disease extent, and intrinsic suscepti-
bility, it is similarly well recognized that a single drug or drug
combination can lead to practical alleviation of symptoms if
not disease reversal. Nonetheless, interindividual differences
in drug response exist and can present a vexing challenge to
any medical intervention. Unwanted heterogeneity in treat-
ment effect can range from mild variation in efficacy to sce-
narios in which some individuals experience severe adverse
drug reactions, and the lack of a means to predict or explain
individual responsiveness to treatment or vulnerability to side
effects frustrates medical decision making.
There is no question that interindividual differences in
drug response have a heritable component (Garrod 1923;
Fox 1932; Snyder 1932; Knox 1958; Alexanderson et al.
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1969; Bertilsson et al. 1993; Johansson et al. 1993; Meyer
2004) or that quantifying those heritable effects would be
useful (e.g., Gamazon and Perera 2012). Yet beyond studies
that focus on candidate genes (e.g., Thelma et al. 2008;
Müller et al. 2013), the heritable architectures of responsive-
ness or vulnerability are largely uncharacterized, resemble
to an unknown extent the architecture of the presenting
complex disease, and are thus unavailable to inform clinical
decisions, pharmaceutical prioritization, or prerequisite ba-
sic research. This lack of information inevitably leads to sub-
optimal policy that, ineluctably, must prioritize average
treatment effects across the human population over poten-
tially more beneficial effects limited to targeted subgroups
(e.g., Kravitz et al. 2004; Wilke and Dolan 2011).
A major obstacle to characterizing heritable architecture
of drug response is technical. Twin studies, a standard way
of estimating heritability that can inform subsequent geno-
mic and clinical research (Martin et al. 1997), offer great
potential value but face challenges in this setting because
they ideally require twins to have identical diseases and
treatments (Vesell 1989; Ozdemir et al. 2005; Rahmioglu
and Ahmadi 2010). Genome-wide association studies
(GWAS) provide valuable information about polygenic in-
heritance of disease traits (e.g., Purcell et al. 2009). How-
ever, applied to drug responsiveness, GWAS face similar
technical difficulties inherent in matching (post hoc or other-
wise) treatment regimes with disease extent, making them
inefficient for estimating such pharmacogenetic quantities.
Moreover, any designed study in humans estimating vulner-
ability to side effects faces additional ethical constraints.
A powerful but underexploited model system for charac-
terizing the heritable architecture of drug response and
vulnerability to side effects is the mouse (Cotsapas 2008).
Using mouse models, many of the factors that complicate
and confound human studies, including the difficulties of
matching dosing regimes, environmental and social contexts,
and genetic background, can be eliminated or varied in a con-
trolled manner through appropriate experimental design. The
potential translational value of mouse experiments for under-
standing drug-response genetics was recently demonstrated
by Harrill et al. (2009). Investigating vulnerability to liver
damage induced by acetoaminophen (paracetamol) across
36 inbred strains from the Mouse Phenome Project (MPP)
(Maddatu et al. 2012), they found that the efficiency of drug
metabolism and the shape of the dose–toxicity curve are both
subject to strain-specific variation. A subsequent association
study for toxicity in these strains helped identify a candidate
gene involved in the immune system (not commonly assumed
of direct relevance to toxicity), and the human ortholog of
this gene showed a replicating association in two independent
human cohorts. More recently, using 27 strains from the MPP,
our group estimated additive heritability of responsiveness to
drug and vulnerability to adverse drug reactions (ADRs) fol-
lowing treatment with haloperidol (Crowley et al. 2012a).
Haloperidol is a highly effective antipsychotic. Like every
antipsychotic currently in use, however, haloperidol has at
least one major side effect and no clinically useful predictors
of vulnerability (Lieberman et al. 2005; Zhang and Malhotra
2011). In a subset of patients it causes disfiguring motor side
effects that are collectively termed extrapyramidal symp-
toms (EPS) (Hsin-Tung and Simpson 2000; Dayalu and Chou
2008; Thelma et al. 2008). With acute treatment, 40% of
patients experience restlessness, involuntary spasms, and/or
muscular rigidity (Simpson 1970). With long-term treat-
ment (.3 months), 35% of patients develop the EPS syn-
drome tardive dyskinesia (TD) (Hsin-Tung and Simpson
2000; Dayalu and Chou 2008), characterized by repetitive,
involuntary, and purposeless movements primarily of the
orofacial region, such as chewing movements and tongue
protrusion (Crane 1968). In 50% of affected patients, TD
is irreversible (Soares-Weiser and Fernandez 2007), and
there is currently no validated and widely accepted treat-
ment (Kaiser et al. 2002).
These extrapyramidal symptoms, the most problematic
side effects of haloperidol, show evidence of familial
clustering (Yassa and Ananth 1981; O’Callaghan et al.
1990; Müller et al. 2001), but their heritability in humans
remains unestimated. Candidate gene studies (Kaiser et al.
2002; Herken et al. 2003; Matsumoto et al. 2004; Lai et al.
2005; Lerer et al. 2005; Patsopoulos et al. 2005; Reynolds
et al. 2005; Bakker et al. 2006; Lee et al. 2007) and GWAS
(Thelma et al. 2008 and references therein; Åberg et al.
2010; Müller et al. 2013 and references therein) have pro-
duced results that are largely inconsistent or that fail to
reach high statistical significance, mostly owing to low
power resulting from small sample size. Armed with so little
information about intrinsic vulnerability, the physician not
only is unable to predict whether a patient will develop TD
but, in the absence of efficacious treatments, also can expect
that many of those for whom haloperidol is prescribed will
be left with a permanently disfiguring condition.
Herein we use an all-by-all cross of eight genetically
diverse mouse strains to investigate how response to halo-
peridol treatment and vulnerability to side effects are affected
by multiple facets of genetic architecture. Our diallel design
enables us to assess not only the additive genetic components
of heritability, as might be estimable from strain survey data,
but also the effects of dominance, epistasis, parent of origin,
and all sex-specific versions thereof. The structure of our
experiment, which explicitly matches drug- and placebo-
treated individuals on genetic background, sex, and parent
of origin, motivates a potential outcomes model of causal
treatment effects (Rubin 2005), which in turn allows us to
connect our work formally with other literature on heteroge-
neous treatment effects in clinical trials and population-based
studies. Building on our previous work investigating ADRs in
mice (Crowley et al. 2012a,b) and developing statistical mod-
els of diallels (Lenarcic et al. 2012), we propose new statisti-
cal methodology for estimating the effect of genetics on the
causal effect of drug treatment.
Our results represent the first attempted comprehensive es-
timation of gross genetic architecture of haloperidol response
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in mice and demonstrate, among other things, the following:
additive effects on ADR susceptibility by NZO/HILtJ and
129S1/SvlmJ, with evidence of effects being magnified when
inherited through the mother, and contrasting additive effects
of NZO/HILtJ and C57BL/6J on plasma drug levels, with
evidence of epistasis. In seeking statistical descriptions of
genetic architecture relevant to future experiments, we in-
troduce new summary measures describing genetic and epi-
genetic effects on treatment response. These measures are
applicable to studies of pharmacoheritability (intrinsic re-
sponsiveness) and toxicoheritability (intrinsic vulnerability)
more generally. Because the eight mouse lines we use are the
founders of the Collaborative Cross (CC) (Collaborative Cross
Consortium 2012) and Diversity Outbred (DO) (Svenson et al.
2012) genetic resource populations, the results of our exper-
iment are directly relevant to the design of follow-up experi-
ments in the CC, the DO, and their derivatives.
Experimental Materials and Methods
Animals
The mice used in this study consisted of inbred and reciprocal
F1 hybrids of the eight founder strains of the Collaborative
Cross (Collaborative Cross Consortium 2012). This includes
five classical strains (short names in parentheses), 129S1/
SvlmJ (129S1), A/J (AJ), C57BL/6J (B6), NOD/ShiLtJ
(NOD), and NZO/HILtJ (NZO), and three wild-derived
strains, CAST/EiJ (CAST), PWK/PhJ (PWK), and WSB/EiJ
(WSB). As shown in Figure 1, we tested all eight inbreds
and 54 of 56 possible reciprocal F1 hybrids; we excluded F1
hybrids NZO 3 CAST and NZO 3 PWK (female 3 male) be-
cause these crosses are unproductive (Chesler et al. 2008). A
total of 270 mice were tested, including 137 females (68
drug, 69 placebo) and 133 males (66 drug, 67 placebo). All
animals were bred at the University of North Carolina from
parents that were fewer than six generations removed from
founders acquired from the Jackson Laboratory. Pups were
weaned at 3 weeks of age and housed two animals per
cage, with one randomly assigned to receive haloperidol
and the other placebo. Animals were maintained on a 14-hr
light, 10-hr dark schedule with lights on at 6:00 AM in a room
maintained at 20–24 with 40–50% relative humidity. Mice
were housed in standard 20 3 30-cm ventilated polysulfone
cages with laboratory grade Bed-O-Cob bedding. Water and
Purina Prolab RMH3000 were available ad libitum. A small
section of PVC pipe was present in each cage for enrichment.
All testing procedures were conducted in strict compliance
with the Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, National Research
Council 1996) and approved by the Institutional Animal Care
and Use Committee of the University of North Carolina.
Haloperidol treatment
The goal was to achieve a human-like steady-state concen-
tration of haloperidol (10–50 nM or 3.75–19 ng/ml) (Hsin-
Tung and Simpson 2000) for 30 days. Previous work
(Crowley et al. 2012a,b) showed that implantable pellets
from Innovative Research of America (Sarasota, FL) yielded
considerably lower coefficients of variation in steady-state
haloperidol concentrations than did injections, implantable
minipumps, or haloperidol in drinking water. Dose-ranging
studies in CC founder strains showed that delivery of
6.7 mgkg21day21 yielded steady-state plasma haloperidol
levels in the 10- to 50-nM range over a 31-day time course
(using pellets from Innovative Research of America de-
signed to release drug at a steady rate for at least 21 days).
Haloperidol pellets were implanted subcutaneously with
a trocar under 2 min of isoflurane anesthesia to minimize
handling stress and pain (Crowley et al. 2012a). Two pel-
lets of incremental dosages were implanted 2 days apart to
compensate for varying body weights and to minimize acute
sedation (dosing regimen as in Crowley et al. 2012a). Placebo-
treated animals were implanted with pellets containing the
same matrix material but no drug.
Measuring drug level after treatment (plasma
haloperidol and brain haloperidol)
Following 31 days of exposure to haloperidol (HAL), blood
was collected into EDTA-treated tubes via tail nick and
centrifuged to isolate plasma. The following day, mice were
sacrificed and whole brains collected. The right hemispheric
portion of the cerebellum was used for brain level measures.
Haloperidol assays were performed using mass spectrometry
by the Analytical Psychopharmacology Laboratory at the
Nathan Kline Institute for Psychiatric Research (Orange-
burg, NY).
Figure 1 Diallel crossing scheme. The number of mice tested (male/fe-
male) per cross is shown, with the most common total sample size being
four: one drug-treated male and one drug-treated female and one pla-
cebo-treated male and one placebo-treated female. A total of 270 mice
were tested, including 137 females (68 drug, 69 placebo) and 133 males
(66 drug, 67 placebo).
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Extrapyramidal symptoms (EPS)
The inclined screen test (Barnes et al. 1990) was used as an
index of Parkinsonian rigidity and sedation. Mice were
placed on a wire mesh screen inclined at 45 and the latency
to move all four paws was recorded (to a maximum of 300
sec). Pilot work indicated that haloperidol-induced EPS
were greatest after acute, rather than chronic, drug treat-
ment. Therefore, EPS was measured at baseline (day 25)
and 48 hr after implantation of the first drug pellet (day 0).
Open field activity (OFA)
Open field activity was measured on days 27 and +28 rel-
ative to the start of drug treatment (day 0). Spontaneous
locomotor activity in the open field Crawley (1985) was
measured for 30 min, using a photocell-equipped automated
open field apparatus (Superflex system; Accuscan Instru-
ments, Columbus, OH; 40-cm wide 3 40-cm long 3 30-
cm high arena). Total distance traveled in 30 min was used
as input for diallel analysis.
Prepulse inhibition (PPI)
The acoustic startle measure was based on the reflexive
whole-body flinch following exposure to a sudden noise
(Dulawa and Geyer 1996). Animals were tested with a San
Diego Instruments SR-Lab system (San Diego), using the
procedure described by Paylor and Crawley (1997). Briefly,
mice were placed in a small Plexiglas cylinder within a larger,
sound-attenuating chamber. The cylinder was seated upon
a piezoelectric transducer, which allowed vibrations to be
quantified and displayed on a computer. Each test session
consisted of 42 trials, presented following a 5-min habitua-
tion period. There were 7 different types of trials: the no-
stimulus trials, trials with the acoustic startle stimulus (40
msec; 120 dB) alone, and trials in which a prepulse stimulus
(20 msec; 74, 78, 82, 86, or 90 dB) had onset 100 msec
before the onset of the startle stimulus. The different trial
types were presented in blocks of 7, in randomized order
within each block, with an average intertrial interval of 15
sec. Measures were taken of the startle amplitude for each
trial, defined as the peak response during a 65-msec sam-
pling window that began with the onset of the startle stim-
ulus. Levels of prepulse inhibition at each prepulse sound
level were calculated as 100 2 [(response amplitude for
prepulse stimulus and startle stimulus together/response
amplitude for startle stimulus alone) 3100]. Pilot work in-
dicated that haloperidol-induced increases in PPI were
greatest after acute, rather than chronic, drug treatment.
Therefore, PPI was measured at baseline (day 26) and 24
hr after implantation of the first drug pellet (day 0). Since
PPIs across different prepulses were highly correlated, they
were reduced to the first principal component for diallel
analysis [principal component (PC)1 explained 77% of the
variation among the PPI change scores].
Vacuous chewing movements (VCM)
Orofacial observations were made on days 25 and +30 rel-
ative to the start of drug treatment (day 0). High-resolution
digital videotapes of orofacial behavior were made by modi-
fying the method of Tomiyama et al. (2001). These methods
are described in detail in Crowley et al. (2012a).
Statistical Models and Methods
We introduce statistical methodology to measure genetic
effects on drug response in a diallel. Starting with the
decomposition of diallel effects and the Bayesian regression
algorithm developed previously by our group in Lenarcic
et al. (2012), we use insights from the Neyman–Rubin po-
tential outcomes framework (Rubin 1974, 2005; Holland
1986) to introduce the concept of an implied “genetic 3
treatment vector”. To estimate this vector, we provide two
methods: a “difference of models” estimator and a “multiple-
impute matched pairs” estimator. We then advise on data
transformation, on the use of “gain” (or “post- minus pre-”)
scores as target phenotypes, on specification of prior dis-
tributions, and on model selection. We conclude by defin-
ing the concept of a diallel treatment-response variance










transformation Female Male All
Weight Body weight Pretreatment Weight (g) log(x) 62 61 62
Brain HAL Brain haloperidol level Post-treatment Concentration (nM) x 60 59 62
Plasma HAL Plasma haloperidol level Post-treatment Concentration (nM) log(x) 61 59 62
EPS Extrapyramidal
symptoms











PPI Prepulse inhibition Pre- and post-treatment PC1 of startle at
5 prepulse levels
ffiffiffiffiffiffiffiffiffiffiffi
x þ 3p 62 61 62
VCM Vacuous chewing
movements
Pre- and post-treatment Movement score: overt +
subtle + tongue +
tremor
log(x) 38 36 38
Listed are the seven primary phenotypes examined before and after drug/placebo treatment within the 83 8 diallel. Phenotypes were transformed prior to statistical analysis.
The final three columns show the depth of coverage across the full diallel.
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projection, a heritability-like measure that relates the ge-
netic, parent-of-origin, sex, and sex-specific effects varied in
the diallel to the total variance in treatment effect of the drug.
A Bayesian model of genetic effects in the diallel
We begin by reviewing the Bayesian linear mixed model for
analyzing inbred diallels proposed in Lenarcic et al. (2012),
which is implemented as a Gibbs sampler in the R package
BayesDiallel. For a single quantitative phenotype yi, mea-
sured for individuals i 2 {1, . . . , n}, using sex and parental
strain information, effects are decomposed into a additive,
b inbreeding, m maternal parent-of-origin, v symmetric
cross-specific, and w asymmetric cross-specific effects and
sex-specific versions thereof denoted fa, fm, fb, fv, and
fw. For individual i with mother j and father k, we model
yi ¼ mþ xTi a|ffl{zffl}
covariates
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where m serves as intercept and xi is an optional vector of
pretreatment experimental covariates, such as information
on length, weight, diet, or sleep regimen of an individual. In
the above equation, Ssex is a 6 12 sign with þ 12 for female and
2 12 for males, such that, for example, f describes the mar-
ginal effect of being female. Cross-specific terms represent
epistasis that is symmetric with respect to the parents (jk
and kj have the same effect) or asymmetric (jk and kj have
different effects) and are defined such that ujk = ukj for u 2
{v, w, fv, fw} with asymmetry induced by operator Sj,k,
which is a 612 sign defined as
1
2 for j , k and 2
1
2 for j .
k. For J = 8 parental strains, there are 8 additive, inbreed-
ing, and maternal coefficients, one dose effect for each
strain, and 8 3 7/2 = 28 symmetric and asymmetric
cross-specific coefficients. Thus, a full model that includes
all possible effects has 160 random-effects coefficients, even
though the diallel itself contains only 2 3 8 3 8 = 128
combinations of conditions (or 128 diallel categories).
Residual, or individual-specific, noise is normally distrib-
uted, ei  N(0, s2), although BayesDiallel can also model
t-distributed noise.
For many of the remaining methods, it suffices to
describe Equation 1 more compactly as





where the vector di encodes all diallel parental-strain and
sex information, and the vector b is a vector of length 160
with coefficients for all a, b, m, v, . . . ,fw effects (collectively,
“diallel effects”).
Modeling causal effects using potential outcomes
We approach estimating causal effects of drug treatment
though the framework of potential outcomes (see Rubin 2005
and references therein). As postulated in Rubin (2005), let
yi{1} be the phenotype of an individual i if it had been treated
with the drug and let yi{0} be the phenotype of individual i if
it had instead received placebo. Define the treatment effect of
the drug on individual i to be the linear difference:
ytreati [ yif1g2 yif0g: (3)
If we could observe both yi{1} and yi{0}, then measuring
this treatment effect would be straightforward. But in prac-
tice, only one of yi{1} or yi{0} can ever be observed for
a given individual. As a result, the treatment effect ytreati
can never be observed directly—a limitation known as the
“Fundamental Problem of Causal Inference” (Holland 1986,
p. 947). The two quantities yi{1} and yi{0} are described as
“potential outcomes”: If individual i was actually assigned
drug treatment, then yi{1} is its observed potential outcome,
while yi{0} is its unobserved potential outcome (or “coun-
terfactual”); if some other individual i9 received placebo,
then its potential outcome yi9{1} is unobserved.
To estimate ytreati for every individual, a potential outcomes
analysis requires assumptions and a method to impute the
unobserved values, yi{1} and yi{0}. That is, for individual i
whose yi{1} value was observed, a model-driven estimate
must be imputed. This is typically achieved either parametri-
cally or through, for example, matching of comparable pairs
of individuals (e.g., Rubin 2006). Care must be taken to con-
sider the treatment-assignment mechanism; placebo should
not, for example, be given only to individuals that inherently
Table 2 Terminology for describing drug, placebo, and drug-response phenotypes using open field activity (OFA) as
an example
Type of outcome Placebo-treated mouse i Drug-treated mouse i9






Gain score OFAgainplacebo;i ¼ OFApostplacebo;i 2OFAprei OFAgaindrug;i9 ¼ OFApostdrug;i9 2OFAprei9






i9 ¼ OFAgaindrug;i9 2OFAgain
⋆
placebo;i9
Starred quantities in the bottom row are unobserved “counterfactuals”, or “potential outcomes”, required to define the treatment effect.
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score higher yi{1} and yi{0}. In our study, treatment was
assigned to individuals at random among genetically identical
cage mates.
Extending potential outcomes to define a genetic 3
treatment vector
The BayesDiallel model in Equation 1 was designed to model
the effect of genetics on a single-outcome measure, but not to
model how genetics modulate the response of individuals to
a drug or, alternatively, how a drug modulates the impact of
genetics. If our sole interest was to measure an “average
treatment effect” (ATE), then we could easily introduce
a treatment indicator with corresponding coefficient in a of
Equation 2 or alternatively use a standard potential outcomes
estimator. It may be, however, that the effect of the drug
differs among well-defined subgroups of the population—
specifically, differing between those with certain combina-
tions of genetics, parent of origin, and sex. In which case,
we seek not to estimate an average but rather to charac-
terize a “heterogenous treatment effect” (HTE) (e.g., Byar
1985; Longford 1999) by constructing a measure that is
relatable to genetic structure of the diallel. We here mod-
ify the framework of potential outcomes to define a vector
that decomposes treatment effects into its many genetic
(additive, epistatic), epigenetic (parent-of-origin), and sex-
specific (sex, sex-by-genetic, and sex-by-parent-of-origin)
targets.
Consider two diallel models governing the phenotype
under assignment of drug or placebo for individual i,
yif1g ¼ mdrug þ xTi adrug þ dTi bdrug þ edrugi
and
under  drug  treatment;
yif0g ¼ mplacebo þ xTi aplacebo þ dTi bplacebo þ eplaceboi under  placebo;
(4)
where edrugi  Nð0;s2drugÞ and eplaceboi  Nð0;s2placeboÞ: In the
above equations, {mdrug, mplacebo}, {adrug, aplacebo}, and
{bdrug, bplacebo} all provide potentially different contribu-
tions in the drug-treated and placebo state, and s2drug and
s2placebo may also differ considerably. Taking the difference of
the above equations, we observe that we can model the
treatment effect ytreati as




















This allows us to identify a genetic 3 treatment vector
btreat [bdrug2bplacebo: (7)
This vector encodes the causal effect of drug varied among all
inheritance combinations and is the key quantity of interest in
the analysis of drug–placebo-treated diallels. Coefficients in
btreat represent drug interaction with every diallel category: sex,
genetics, parent of origin, and their combinations. For instance,
atreatB6 ¼ adrugB6 2 aplaceboB6 is the additive effect of the B6 genome on
the effect of treatment using drug rather than placebo.
Three additional treatment interaction effects are thus
defined,
mtreat[mdrug2mplacebo ðintercept treatment effect of drugÞ






where mtreat represents the overall shift in intercepts of the
two models, and atreat estimates the extent that pretreat-
ment covariates (e.g., pretreatment body weight) provide
additional resistance or susceptibility to drug.
Regarding the covariance of the residuals for drug and
placebo potential outcomes, Covðedrugi ; eplaceboi Þ ¼ rsdrugsplacebo;
we make the assumption that correlation r $ 0. With this
assumption, Equation 6 suggests that noise is greatest when
r = 0, or etreat  Nð0;s2drug þ s2placeboÞ; with r = 1, then etreat
N(0, (sdrug 2 splacebo)2). Since setting r = 0 assumes the
largest effect of noise, we rate the performance of estimators
for btreat (described next) on this worst-case scenario.
Estimating causal effects: Difference of
models approach
A straightforward approach is to fit BayesDiallel separately




. Because their priors are independent, posteriors for
Table 3 Effects used in the simulation study
Strain no.
1 2 3 4 5 6 7 8
Baseline additive 210 28 24 21 1 3 7 12
Baseline sex 3 additive 26 6 25 5 24 4 23 3
Baseline maternal parent origin 0 0 0 0 0 0 0 0
Treatment difference
Additive treatment effect 25 3 1 22 4 22 3 22
Sex 3 additive treatment effect 22 2 2 22 3 23 23 3
Maternal treatment effect 23 3 23 3 23 3 23 3
Listed are diallel effects for baseline placebo and for treatment effects differences;
all other effects were simulated to be zero. Sample size in each simulation is 115 of
the 128 possible diallel categories selected with replacement. Average overall
treatment effect is 2. Note that although we simulate no parent-of-origin maternal
effect for placebo individuals (zero for all values), a maternal differentiating effect is
observed in drug-treated samples, and thus the drug 3 maternal effect is present.
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bdrug and bplacebo are also independent and separable. This
means that Gibbs samples ðb̂drugÞðtÞ and ðb̂placeboÞðtÞ; sampled





We call this a “difference of models” (DoM) approach.
DoM is equivalent to fitting all observed data under
the assumption that bivariate noise covariance Covðedrugi ;
e
placebo
i Þ ¼ rsdrugsplacebo has r = 0 (i.e., potential outcomes
residuals for an individual are uncorrelated). If r . 0, then
DoM will overrepresent statistical uncertainty about
parameters.
Estimating causal effects: Multiple-impute matched
pairs approach
In our drug–placebo diallel, every drug-treated mouse i with
mother j and father k has at least one matching mouse i9 of
the same sex who received placebo. This enables a “matched
pairs” (MP) approach, where we estimate mouse i’s drug
response as
ŷtreati ¼ ydrugi 2 yplaceboi9 : (9)
In a completely balanced experiment with n mice, this pro-
duces n/2 drug response estimates based on n/2 matched
pairs. Setting ŷtreati as the outcome in the BayesDiallel re-
gression yields an estimator of btreat.
In our experiment multiple mice were tested under each
experimental condition, and the unpredictably of mouse
production and maintenance led to sporadic imbalance of
drug vs. placebo mice per diallel category. In many cases,
therefore, a given mouse i would have multiple eligible
matches. For example, with two drug-treated mice {(A,
B)} and three placebo-treated mice {(C, D, E)}, all in the
same diallel category (e.g., all B6 3 WSB males), six match-
ings are possible: {(A, C), (B, D)}, {(A, E), (B, D)}, {(A, D),
(B, C)}, {(A, E), (B, C)}, {(A, C), (B, E)}, and {(A, D),
(B, E)}. Each of these discards one placebo-treated mouse.
To ensure our matching does not induce bias, we therefore
perform a multiple imputation of matchings: of the com-
binatoric set of all possible matchings that use as many
mice as possible, we sample 10 eligible matchings, per-
form Gibbs sampling of the BayesDiallel model on each,
and then pool the Gibbs samples, noting that all matchings
should receive equal weight a priori. This produces our
final “multiple-impute matched pairs” (MIMP) estimate
of btreat. Note that in the case of a single, perfectly matched
sample, MIMP reduces to MP; for simulations and theory
we will therefore consider MP only (and not multiple
imputation).
Because in our experiment mice in the same diallel
category were typically housed in the same cage, the MP
implicitly controls for environmental effects of housing and,
by proxy, time. Even if a large cage effect Ei perturbed
a drug-treated mouse’s phenotype, such that
ydrugi ¼ xTi adrug þ dTi bdrug þ Ei þ ei; (10)
then for matching mouse i9,
yplaceboi9 ¼ xTi aplacebo þ dTi bplacebo þ Ei þ ei9: (11)
Subtracting Equation 10 from Equation 11 removes Ei from
the model. Thus, optimally designed matched-pair experi-
ments naturally remove blocking effects from a noise model,
provided that matched pairs are contained within a block.
Transformations, epistasis, and interpreting effects
For simplicity we have thus far assumed that yi{1}, yi{0},
and ytreati are subject to residual noise that is normally dis-
tributed. Measures such as OFA, which counts the total
number of beam breaks 2 [0, 50000), or blood haloperidol
concentration may on their original scale break this assump-
tion. As is standard in regression, to raw phenotype values ~yi
we applied suitable normalizing transformations yi ¼ f ð~yiÞ;
using common monotonic functions (log, x1/2, . . .) that im-
proved Gaussianity of the noise.
Table 4 Summary of simulation performance between MP, DoM, and DoM with cage environmental noise removed,
fitting a full model and using model selection, and Oracle MP estimator, which fits only true effects
Summary statistic MP DoM DoM, no cage noise Oracle MP
Full model
Posterior-mean L2 error 21.03 (8.27) 21.34 (7.14) 24.04 (7.34) 5.46 (2.32)
MC L2 error, all 127.93 (30.24) 207.59 (72.2) 159.4 (38.82) 11.05 (2.47)
95% C.I. width 3.01 (0.22) 3.9 (0.27) 3.32 (0.22) 1.7 (0.12)
95% C.I. coverage 99.6 (0.6)% 99.9 (0.2)% 99.7 (0.5)% 95.6 (4.7)%
Nonzeros identified 91.7 (5)% 86.1 (5.4)% 91.9 (4.7)% 96.2 (3.5)%
Selection
Posterior-mean L2 error 5.24 (2.33) 5.4 (2.46) 5.07 (2.45)
MC L2 error 31.85 (15.8) 47.43 (17.75) 34.11 (14.34)
95% C.I. width 1.77 (0.13) 2.16 (0.13) 1.71 (0.11)
95% C.I. coverage 96.2 (4.4)% 98 (3.1)% 96.1 (4.3)%
MIP nonzeros 99.99 (0.02)% 73.9 (1.8)% 72.9 (1.3)%
MIP zeros 16.4 (3.6)% 15 (2.3)% 13.3 (2.3)%
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In choosing a transformation f, we balance interpretabil-
ity of parameter estimates with a concerted attempt to sat-
isfy the model’s assumptions of residual normality; when the
two are in strong conflict, we favor satisfying residual nor-
mality for the following reason. The BayesDiallel model
includes a comprehensive set of marginal effects that try
to explain phenotypic variation through the linear combina-
tion of distinct strain-specific effects; but it also provides
extensive scope for identifying statistical interactions be-
tween strains in the form of cross-specific effects (i.e., epis-
tasis that may or may not depend on parent of origin and/or
sex). A highly skewed phenotype when analyzed without
transformation will often induce strong statistical interactions
that disappear when it is reanalyzed under a normalizing
transformation. These interactions are therefore “removable”
(Berrington De González and Cox 2007) and potentially say
more about the inadequacy of our Gaussian noise assumption
than they do about genetic architecture. To ensure parsimo-
nious inference we thus apply normalizing transformations
where possible (listed in Table 1), with the implication that
estimated effects for, e.g., body weight combine additively on
the log scale but multiplicatively on the original scale.
Pretreatment, post-treatment, and gain scores
Phenotype measurements were available before and after
treatment for some phenotypes [EPS, OFA, PPI, and vacuous
chewing movements (VCM)], but not others (plasma HAL,
brain HAL). The causal effect modeling described above does
not require pretreatment measurements to be valid, since
randomized assignment means that mice in the same diallel
category can be assumed to start at the same baseline for each
behavioral phenotype— at least in expectation. Nonetheless,
including pretreatment measures in the analysis avoids reli-
ance on this expectation, accounts better for individual noise,
and therefore can be used to improve estimates of btreat.
Consider an individual i, a measurable phenotype yi, and
an experiment in which the individual receives either a drug
treatment or a placebo treatment. Suppose individual i is
assigned to receive the drug. Let yprei be the phenotype of
the individual before treatment and let ypostdrug;i be the pheno-
type following treatment with the drug. The “gain score” for
drug-treated individual i is defined as
ygaindrug;i¼ ypostdrug;i 2 yprei   : (12)
This is not the same as the drug response because it in-
corporates effects of multiple confounding factors unrelated
to the drug itself, including: the passage of time; physical
aspects of the implantation procedure; learning effects on
the tests, and so on. The gain score of a placebo-treated in-
dividual is defined similarly as
ygainplacebo;i¼ ypostplacebo;i2 yprei   : (13)
Because individuals were assigned randomly to drug or
placebo, we can use the same yprei in either case. For our
causal effect modeling, we specifically model potential out-




One might argue that because yprei is not observed in the
model, specifically that since
ygaindrug;i2 y
gain






¼ ypostplacebo;i 2 ypostplacebo;i;
(14)
it is unnecessary to introduce it in the potential outcomes
framework. On the contrary, the role yprei plays in improving
estimates is subtle but valuable. In the DoM approach, ygaini
has lower noise variance than yposti and therefore allows us
to estimate bdrug and bplacebo more precisely. Note that when
ygaini is used as an input, it must be understood that b
drug is
a vector that models ygaini ; the change in performance, and
not yposti : In the MP estimator, y
gain
drug;i ¼ ypostdrug;i 2 yprei and
ygainplacebo;i9 ¼ ypostplacebo;i9 2 yprei9 are measured on different individ-
uals i and i9. Thus we implicitly assume ygainplacebo;i9; the ob-
served gain score for individual i9, is close to ygainplacebo;i;
which is the unobserved gain score for individual i.
In our drug–placebo diallel, the pretreatment, post-
treatment, and gain score phenotypes are all potentially
influenced by covariates and diallel category and so can
be modeled as univariate phenotypes (as in Equation 2;
see example in Table 2).
Bayesian hierarchical priors
The BayesDiallel model includes a few coefficients that we
consider “fixed”—that is, not appropriate for grouped mod-
eling. These include m, binbred, f, and finbred, which are
overall effects averaged over strains. To these, we give in-
dependent vague priors of the form N(0, 10)3. Pretreatment
covariates in a are also typically ungrouped in this study and
so are similarly modeled as independent fixed effects.
Other effects, such as the strain-specific additive effects
{a1, . . . , a8} = {aAJ, aB6, . . . , aWSB}, we consider to be
associated together in a group. These are modeled as if
Figure 2 Phenotyping protocol. Four behavioral phenotypes were mea-
sured prior to drug treatment (predrug) to establish baseline levels. PPI
and EPS phenotypes are most responsive to acute haloperidol treatment
and so were next measured within 48 hr of drug treatment. OFA and
VCM phenotypes are responsive to chronic haloperidol treatment and so
were next measured 1 month following drug treatment.
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drawn from a constrained normal distribution whose var-
iance is itself estimated. For instance, the group prior on
the J = 8 additive coefficients a1, . . . , a8 takes the form





but subject to a1 þ a2 þ . . .þ a8 ¼ 0
(15)
t2a  Inverse x2ðd:f: ¼ 0:5;mean ¼ 1Þ:
In the present study, we use a more efficient version of
the group prior of Lenarcic et al. (2012); this advance is
described in Appendix A.
Covariates xi or response variables ~y with especially large
or small ranges (e.g.,.105 6 103 are scaled to a more stable
range [e.g., 0 6 100 order to ensure both numerical stability
and that priors on effects are only weakly informative (as in,
e.g., Gelman and Hill 2007)].
Randomization assumption
We make a last, relevant assumption to causal research,
which can be interpreted as a diallel equivalent to a “stable
unit treatment value assumption” (SUTVA) (Rubin 2005).
SUTVA commonly assumes that treatment assignment to
one individual i negligibly affects phenotypes of other indi-
viduals i9. Because placebo and drug-treated individuals in
the same diallel category are caged together, we do not
consider SUTVA to hold. Only individuals in different diallel
categories are independent. Treatment effect is thus defined
herein as being under conditions of paired containment with
an alternately treated twin. Because the treatment assign-
ment mechanism is fully randomized and not based upon
pretreatment phenotypes, we consider the DoM and MP
estimators to be valid for these conditions.
Model selection
Estimation of diallel effects described above proceeds under
the assumption that all of the 13 inheritance classes are
active; that is, effects in each class make a contribution to
the phenotype value that could be small but only with
infinitesimal probability that is exactly zero. This assump-
tion is justified by the experimental design, in which
a relatively small number of interventions are knowingly
applied (genetics, sex, parent of origin, treatment) and the
goal is to estimate their effects. An alternative perspective,
leading to a more parsimonious account of genetic architec-
ture, is provided by Bayesian model selection, where each
class is assigned a substantial prior probability (0.5) of
making zero contribution to the phenotype (equivalent to
this class being excluded from the model). We use the
exclusionary Gibbs group sampler of Lenarcic et al. (2012)
to then evaluate how much the observed data update this
probability in the posterior, examining each class’s posterior
model inclusion probability (MIP). MIPs near 1 provide ev-
idence for retaining an inheritance class, MIPs near 0 provide
evidence for its exclusion, and MIPs near 0.5 indicate that
the observed data insufficiently support an informed deci-
sion. For reporting purposes, MIPs within the ranges (0.05,
0.25] or [0.75, 0.95) represent positive evidence, (0.01, 0.05]
or [0.95, 0.99) represent strong evidence, and [0, 0.01] or
[0.99, 1] represent very strong to decisive evidence, approx-
imately following the corresponding Bayes factor interpre-
tations in Kass and Raftery (1995).
Using the MP estimator, MIPs identify significant treat-
ment effects; i.e., atreatB6 ¼ adrugB6 2 aplaceboB6 6¼ 0: When using the
DoM estimator, MIP is calculated twice: once for drug-treated
individuals and once for placebo-treated mice. These DoM
MIPs represent the importance of a group of effects separately
to a drug or a placebo model. We argue that the maximum of
these two MIPs is the most practical single score for model
inclusion to be used with the DoM approach, since the first
goal of MIP is to find potentially activated groups of interest.
Diallel variance projection: A heritability-like summary
In addition to reporting estimates of 160 parameters from
the BayesDiallel model, it is convenient to summarize an
Table 5 Diallel variance projection (VarP) for baseline phenotypes
Diallel inheritance class Body weight EPSpre OFApre PPIpre VCMpre
Overall inbreeding (B) 1.17 (0.52, 1.85) 0.12 (0.00, 0.45) 0.64 (0.01, 1.33) 0.13 (0.00, 0.46) 0.52 (0.00, 2.09)
Overall sex (S) 13.75 (10.19, 17.00) 0.75 (20.00, 1.72) 1.65 (0.48, 3.06) 6.02 (3.05, 8.67) 0.65 (20.09, 2.56)
Overall sex 3 inbreeding (BS) 20.22 (20.51, 0.13) 0.04 (20.06, 0.23) 0.10 (20.10, 0.41) 0.31 (20.23, 0.99) 0.42 (20.13, 1.62)
Additive (a) 60.46 (45.75, 75.68) 38.62 (27.13, 49.62) 53.18 (43.68, 62.57) 26.10 (13.54, 37.58) 10.19 (1.41, 21.05)
Inbreeding (b) 0.37 (23.31, 4.09) 10.14 (4.02, 16.27) 8.85 (4.73, 13.05) 1.35 (21.46, 3.97) 2.93 (20.48, 8.53)
Parent of origin (m) 4.31 (0.14, 9.24) 3.09 (1.02, 5.55) 1.39 (20.04, 3.18) 2.38 (20.06, 4.97) 4.49 (0.21, 10.36)
Symmetric epistasis (v) 4.99 (26.26, 15.94) 5.86 (20.51, 12.89) 3.27 (21.65, 9.46) 23.71 (14.03, 34.21) 7.19 (1.12, 14.06)
Asymmetric epistasis (w) 2.93 (20.72, 6.95) 3.79 (1.25, 6.67) 3.86 (1.50, 6.36) 3.00 (0.55, 5.31) 3.58 (0.34, 7.93)
Sex 3 additive (aS) 0.56 (20.64, 1.78) 1.23 (0.14, 2.50) 0.25 (20.03, 0.78) 1.63 (0.06, 3.27) 3.33 (0.10, 7.97)
Sex 3 inbreeding (bS) 0.33 (20.19, 0.90) 0.35 (20.09, 0.95) 0.04 (20.02, 0.19) 0.50 (20.11, 1.26) 0.75 (20.30, 2.52)
Sex 3 parent of origin (mS) 0.64 (20.47, 1.94) 0.72 (0.03, 1.66) 0.22 (20.01, 0.68) 0.88 (20.07, 2.05) 2.47 (0.12, 5.83)
Sex 3 symmetric epistasis (vS) 1.48 (0.23, 3.10) 1.24 (0.31, 2.48) 0.36 (20.02, 1.33) 2.49 (0.81, 4.33) 2.07 (0.19, 4.48)
Sex 3 asymmetric epistasis (wS) 1.49 (20.05, 3.20) 1.05 (0.19, 2.08) 0.23 (20.02, 0.95) 1.70 (0.40, 2.97) 2.35 (0.25, 5.10)
Total variance explained 92.27 (90.60, 93.89) 66.99 (62.18, 71.89) 74.05 (70.50, 77.77) 70.19 (65.80, 74.74) 40.94 (29.04, 52.19)
Unexplained variance 7.73 (6.11, 9.40) 33.01 (28.11, 37.82) 25.95 (22.23, 29.50) 29.81 (25.26, 34.20) 59.06 (47.81, 70.96)
For each phenotype (column) is listed the predicted percentages, along with 95% credibility intervals, of variance that would be attributable to each class of effect in a future
complete diallel of the same parental strains.
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overall relative contribution from each of the 13 inheritance
classes. In explaining the phenotype, we provide a measure
that aggregates the contribution of linear effects together
(assessing joint contribution of all a1, a2, . . . , a8) and also
describe the contributions of multiple classes (a, b, m, . . . ,
fv). Superficially, this is similar to a partitioning of “herita-
bility” (e.g., Mather and Jinks 1982; Lynch and Walsh 1998)
but includes other effects, such as sex and parent of origin,
that are arguably nongenetic. Our decomposition is explic-
itly prospective, with the practical goal of forecasting the
variance contributed by each class in an idealized, future
diallel of the same founders.
For a multivariate, multistrain decomposition involving
design matrix D = (d1, . . . , dn)T, we apply a property of the
hat matrix, P= D[DTD]21DT, which is also known as a “pro-
jection”matrix, to decompose the sum-of-squared prediction
error into modeled components and noise (Neter et al.
1996). If ba is the subset of coefficients of b corresponding
to the additive effects a, and di,a are the design matrix val-










ðyi2ŷiÞ2; for ŷi ¼ dTi b; (17)
where SSa þ SSb þ . . . SSfw added to SSnoise equals the total
sum of squares of y. Since we do not know ba, but have
statistical draws from a posterior b̂
ðtÞ
a for Gibbs samples
t, . . . , T, we use those Gibbs samples to estimate and re-
port confidence measures for the estimated sum-of-squares
contributions.
Although we may not have analyzed a diallel experiment
that was complete and balanced, we still choose to express
predicted variance in terms of a balanced, complete diallel.
We thus project our particular diallel experiment onto future
experiments based on a standard-sized diallel population.
Instead of using observed yi, we use the Gibbs sampler to
simulate ~yðtÞi ¼ ~d
T
i b
ðtÞ; that is, posterior predictive mean
draws for future mice. If ~di for i 2 {1, . . . , 2J2} is the design
set of all i mice in a future, full, complete balanced diallel,




yeðtÞi 2 yðtÞ~dTi b̂ðtÞa : (18)
Assuming that the future experiment is designed to ensure
that covariates are either absent or held at a stable value or
otherwise controlled, we estimate the diallel population mean,
at Gibbs iteration t, to be Y ðtÞ ¼ ð2J2Þ21Pi~dTi bðtÞ:
For the additive inheritance class, the posterior mean









When reported for all inheritances classes, we call this
partitioning the diallel “variance projection” (VarP), since it
is both a linear algebra projection of the components of
variance and a prediction for the variation of future diallels.
Note that p2a can conceivably be negative and that cred-
ibility intervals for p2a can include zero. This is a consequence
of having multiple groups of effects (a, b, . . . , fw) competing
against each other to predict Yi. In extreme cases, a param-





;wYi: This serves our purposes for
a consistent statistical estimator: having credibility inter-
vals that include zero, for instance, a [20.01, 0.02] inter-
val, means that we do not automatically assume that every
component a, b, . . . , fw contributes positive, nonzero
Figure 3 Overall drug response data.
Gain scores (post- minus prevalues) were
collapsed across both sexes and all gen-
otypes to gather a general impression of
the effect that placebo and haloperidol
had on each phenotype. Shown is the
mean gain score for each phenotype.
Haloperidol, on average, tended to de-
crease open field activity, increase rigid-
ity on the inclined screen, increase
vacuous chewing movements, and in-
crease prepulse inhibition.
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information to the prediction of Yi. When credibility inter-
vals exclude zero, such as when we find statistically signif-
icant epistasis in our experimental results, we are expressing
strong evidence in the data that this group of effects is im-
portant to the model. Simulations in Appendix B show that
this is a reliable method to test the presence of contribution
to phenotypic variance.
Genetic treatment response variability: Summary
of gene 3 treatment effects
The variance projection framework extends immediately to
measuring “heritability of drug response” or, more accu-
rately, the relative contribution of diallel effects to HTE.
We call this form of VarP the diallel treatment-response
variance projection (TReVarP). Whereas in VarP, genetic
contributions are expressed as a proportion of the total phe-
notypic variance Var(Yi), in TReVarP, we target a subcompo-
nent of this variance. For a future individual i, the variance




 ¼ VarðYif1g2 Yif0g2 ðYf1g2 Yf0gÞÞ; (20)
where Yf1g is the average performance of drug-treated in-
dividuals in the diallel and Yf0g is the average of placebo-
treated individuals; this is used as the denominator for
TReVarP. The difference D[ Yf1g2 Yf0g is the average
treatment effect; at Gibbs sample draw t we define this as
D




















where the expectation is taken over noise, and ~di is the de-





is then the posterior mean for the average treat-
ment effect.
The numerator sums of squares for TReVarP are defined




















































	2   ; (23)
which can be measured with credibility intervals similarly to
VarP.
The MPmethod can estimate the same TReVarP as the DoM
by substitution of ~Y
match
i 2 Y
match for ð~Ydrugi ÞðtÞ 2 ð~Y
drug
i ÞðtÞ 2D
and ðb̂matcha ÞðtÞ for ðb̂
drug
a ÞðtÞ 2 ðb̂
placebo
a ÞðtÞ   : Thus, our extension
of VarP into TReVarP is compatible with the concept of a de-
nominator representing only treatment-response variance as in
Equation 20.
Simulation Results
Theoretical properties of DoM and MP (i.e., MIMP with
a single, perfectly matched sample), described in Appendix
C, suggest that under maximum-likelihood estimation the
two approaches give point estimates that are identical but
with standard errors that are different. Under Bayesian
shrinkage, and when treatment effects are smaller than ge-
netic effects, MP estimators are seen to have less variability
whereas DoM estimators have less bias. From a pure esti-
mation standpoint, the two approaches thus have different
trade-offs. Other trade-offs relate to experimental design:
when placebo vs. control groups are difficult to match, the
DoM estimator more easily accommodates extra covariates;
when matched pairs are housed together, the MP estimator
can cancel out environmental noise. We assess relative per-
formance of these methods under different assumptions
through simulation.
Figure 4 Phenotype correlations at baseline (predrug) and after drug treatment (postdrug and postplacebo). OFA distance traveled was used to
represent the set of largely correlated OFA measures.
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We simulated matched pairs of placebo and control
animals (n = 115), sampling with replacement from the
128 = 2 3 8 3 8 possible diallel categories and simulat-
ing treatment effects from only three inheritance classes
(Table 3).
Individuals were given i.i.d. noise of magnitude
s2drug ¼ 2 and s2 control ¼ 1, and every matched pair was
additionally perturbed with a single Ei  N(0, 1) environ-
mental effect. This environmental effect is naturally can-
celed out by MP but cannot be disentangled using DoM.
We therefore compared estimates from the two procedures,
both with and without environmental noise. Treatment
effects were then estimated using the “full” BayesDiallel
model, which includes all parameters in Equation 1, with
and without the application of model selection. We also
considered the performance of an “Oracle match” model,
which is a matched pairs estimate made artificially prescient
that the true model contains only additive, sex 3 additive,
and maternal effects. Average performance in 400 simula-
tions is reported in Table 4.
All of the methods are robust in that they return $95%
coverage of effect values. But the estimators using the full
BayesDiallel model significantly overcover, with 95% credi-
bility intervals that cover the truth 99.9% of the time. The
full BayesDiallel model is inherently overspecified: even in
a fully sampled, replicated diallel cross specific effects vjk
and additive effects aj confound with each other, in that
a model composed completely of cross-specific effects could
completely reproduce an additive model. In the analysis of
real data sets, we are unaware of and cannot expect there to
be no cross-specific terms vjk. But, when we fit these simu-
lated data, for which only aj, mj, and D
a
j are nonzero, the
estimators using model selection do have narrower credibil-
ity intervals that also more appropriately cover the truth
(96.2%, 98%, and 96.1%, respectively).
For our purposes we must accept overconservative
intervals as necessary for testing a complex model that
includes epistasis and realize that some true (i.e., truly non-
zero) effects will go undetected. We see that the percentage
of true effects identified, i.e., the percentage of times the
95% credibility interval for a true effect excludes zero, hov-
ers near 90%.
Integrated L2 error was measured using the Markov






and L2 error of posterior mean point estimates was mea-
sured as
P
jð~bj2b truej Þ2; where ~bj is the posterior mean.
The number of true treatment effects identified was
recorded as the number of times credibility intervals for
those effects excluded zero. The full model is shown to dis-
tinguish true effects from noise .85% of the time. MIPs
Figure 5 Genetic architecture of se-
lected phenotypes in the drug–placebo
diallel. A shows for pretreatment weight
and post-treatment drug levels an aggre-
gated summary of the diallel variance
projection (VarP), a breakdown of rela-
tive contributions for different classes of
inheritance acting in the diallel. Whereas
the full VarP (Table 5) splits phenotypic
variance into 13 diallel effect classes,
these plots show 7 aggregated classes,
where some classes are pooled for clar-
ity. Pooled classes are as follows (diallel
effect group in parentheses): parent of
origin (m + w), epistasis (B + b + v),
sex-specific parent of origin (mS + wS),
and sex-specific epistasis (BS + bS + vS).
Stacked bars (left) show VarP point esti-
mates, and bar charts (right) show 95%
credibility intervals. B shows the VarP for
treatment response phenotypes (TReVarP),
that is, the genetic architecture of halo-
peridol response for the behavioral phe-
notypes measured.
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given for the nonzero effects average .75%, whereas MIPs
for the zero effects are notably lower at 18%.
Here in its ideal setting, the MP model has superior
power—even more so when given oracle information. Even
though in this setting the DoM is at a disadvantage, we see
that DoM is nonetheless statistically sound and does not
posit epistatic effects from environmental noise. What is
surprising is that DoM’s resistance to bias makes its posterior
mean seem, on average, superior to the MP estimator—even
seeming to benefit from environmental noise. This is a con-
sequence of Appendix C’s Equation C1, which shows that the
bias of DoM is less when noise is balanced, as in our envi-
ronmental noise model. Note that, despite a smaller bias for
its posterior mean, the DoM estimator does not have more
statistical power to confirm significant effects.
Experimental Results
A diallel cross of inbred mouse strains was generated to
investigate the effect of genetics, sex, and parent of origin
on response to chronic haloperidol treatment. The parents
used were the eight founder strains of the Collaborative
Cross. From these eight founders was generated an almost
complete diallel (Figure 1), including replicates of all eight
inbreds, and 54 of 56 possible reciprocal F1 hybrids (the 2
hybrids NZO 3 CAST and NZO 3 PWK are unproductive).
For each of the 62 genetic combinations available, cage
mates of each sex were randomly split into two treatment
groups: drug (66 males, 68 females) and placebo (67 males,
69 females). The resulting 270 mice entered a 6-week phe-
notyping protocol (Figure 2, Table 1). Prior to receiving
drug or placebo, mice were weighed and phenotyped for
the following behavioral measures: EPS, OFA, PPI, and
VCM. These measures were chosen to help quantify the se-
verity of potential adverse reactions to subsequent haloper-
idol treatment. Within 48 hr of receiving drug or placebo,
mice were phenotyped a second time for EPS and PPI—
these phenotypes being most responsive to acute haloperi-
dol treatment. Following 1 month of chronic treatment,
mice were phenotyped a second time for OFA and VCM—
these phenotypes being more responsive to chronic haloperidol.
At this time, drug-treated mice were also assayed for halo-
peridol levels in brain and plasma (brain HAL and plasma
HAL; see Table 1). Phenotypes collected before treatment
were termed “baseline” or “pretreatment” phenotypes and
those collected afterward were termed “post-treatment”.
The change in value from pre- to post-treatment for a given
treatment class (drug or placebo) was termed the gain score.
A statistical estimate of the change in gain score moving
from placebo to drug treatment was termed the “drug re-
sponse” or “treatment effect”. This terminology is summa-
rized in Table 2.
Our diallel design allowed us to contrast phenotypes of
animals measured on different genetic backgrounds, alter-
nating both parent of origin and sex. Each of the 8 3 8 3
2 = 128 combinations of these was termed a “diallel cate-
gory”; for example, Figure 1 shows that mice were available
for all but 5 diallel categories. Phenotypes collected on mice
in each diallel category (File S2) were used to inform the
BayesDiallel statistical model (see Statistical Models and
Methods), which estimates 160 effects parameters (“diallel
effects”) that together describe how much a phenotype is
affected by differences in sex, parental strain combination,
and their interaction. Diallel effects are grouped into 13 dis-
tinct inheritance classes, which may be further categorized
into overall effects (sex, S; inbreeding, B; and sex-specific
inbreeding, BS), related groups of strain- or cross-specific
effects (additive, a; inbreeding, b; maternal, m; symmetric
epistatic, v; and asymmetric epistatic, w), and sex-specific
versions of those grouped effects (aS, bS, mS, vS, and wS; see,
e.g., first column of Table 5). Throughout, diallel effects and
predictions based on the BayesDiallel model were estimated
using MCMC, with estimates for each analyzed phenotype
based on 2500 posterior samples collected on five indepen-
dent MCMC chains.
It was expected that the large-scale intrinsic differences
that accompany changes in diallel category (e.g., changing
parental strains, changing parent of origin between the
same parental strains, changing sex, or multiples of these
at once) would affect all aspects of behavior and drug re-
sponse to some degree. The goal of this experiment was to
estimate the magnitude, direction, and relative contributions
of these different types of effects. From this we hoped to de-
velop a clearer picture of how genetics, parent of origin, sex,
and their interactions modulate response to haloperidol—in
particular, vulnerability to its side effects.
Overall effects of haloperidol treatment
Effects of haloperidol averaged across genotype and sex are
reported in Figure 3, which for each phenotype compares
gain scores of drug- and placebo-treated mice. Consistent
with our previous work (Crowley et al. 2012a), haloperidol,
on average, tended to decrease activity (OFA measures) and
increase the following: extrapyramidal side effects (EPS,
VCM, and stereotypy), PPI, Parkinsonism, and TD-like and
antipsychotic effects. As expected, some of these outcomes
were correlated (Figure 4): for example, brain and plasma
Figure 6 Model inclusion probabilities (MIPs) of diallel effect groups in
baseline phenotypes. MIPs near 1 (red) indicate strong evidence for a con-
tribution to the phenotype, MIPs near 0 (blue) indicate evidence of neg-
ligible or zero contribution, and MIPs near 0.5 indicate that the data
provide little evidence for or against inclusion.
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drug levels (r = 0.46), plasma drug levels with EPS severity
(r = 0.29), OFA measures with each other, and all five
stimulus variants of PPI with each other (not shown). For
subsequent analysis, PPI was represented by its first princi-
pal component, and OFA was represented only by OFA dis-
tance (Table 1; details in Experimental Materials and
Methods).
Diallel effects on baseline phenotypes: Diallel effects were
estimated for each of the baseline (pretreatment) pheno-
types listed in Table 1. For each phenotype, Table 5 reports
the percentage of variance explained by each of the 13 di-
allel effect classes, along with 95% highest posterior density
(HPD) intervals (akin to traditional confidence intervals).
Although resembling a breakdown of the broad-sense heri-
tability, we describe each sequence of percentages formally
as a diallel VarP because it uses out data to predict variance
contributions in a perfectly balanced, complete, future di-
allel. In our VarP results, HPD intervals for individual classes
(a, b, m, . . . ,fw) can include zero or stretch to negative
percentages; the latter indicates with some posterior proba-
bility a class has a negligible contribution (possibly due to
correlation in the design matrix with other classes). HPD
intervals that do not include zero we consider to be statisti-
cally significant at 95% credibility. HPD intervals for all 160
diallel parameters, including those for each strain or strain
pair, are reported in Supporting Information, File S1.
An alternative view of the results is provided by model
selection. Our model selection analysis judges the evidence
for and against inclusion of each class of effects under the
starting condition that there is a 0.5 probability a priori of
that class making no contribution to the phenotype whatso-
ever (Figure 6). The resulting posterior MIPs are interpreted
as follows: high (close to 1) for classes of effect deemed
essential to the model fit, low (near 0) for those with ap-
parently negligible effects, and in the middle (0.5) for
those whose importance, given the data collected so far,
remains uncertain (more guidelines for interpretation in Sta-
tistical Models and Methods).
Body weight was the only nonbehavioral baseline phe-
notype measured and so is a useful reference point owing to
its ubiquity in genetic studies. It is shown to be highly
heritable (Figure 5), with noise contributing only 6–9.4%
to the total variance, strong effects of additive genetics
Figure 7 Highest posterior density (HPD) intervals of diallel effects on body weight. For each effect parameter, thin and thick horizontal lines,
respectively, give 95% and 50% HPD intervals, and vertical break and dash give, respectively, the posterior median and mean. A shaded vertical line
indicates zero. Parameter names follow Equation 1 and Lenarcic et al. (2012). These estimates, measured on body weight prior to drug treatment,
strongly replicate those seen in the independent diallel study of Lenarcic et al. (2012).
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(VarP[a] ’ 46–76%, Table 5; MIP[a] ’ 1, Figure 6) and sex
(VarP[S] ’ 10–17%, MIP[S] ’ 1), and a small effect of par-
ent of origin (VarP[m] = 0.14–9%; MIP[m] = 0.85; Figure
6). The HPD intervals for the diallel effects (Figure 7)
showed a pattern strikingly similar to those we reported
previously on an independent diallel from the same parental
strains (Lenarcic et al. 2012). The congruence of our results
on these two populations, despite no attempt to match lab-
oratory conditions or timing, strongly supports the robust-
ness of our general approach.
Although pretreatment behavioral phenotypes were less
heritable than body weight, diallel effects nonetheless
explained between 41% and 74%, leaving 25–59% attrib-
uted to noise (Table 5).
OFA was the best-explained behavioral phenotype (pos-
terior mean of VarP[total] ’ 74%). It showed strong addi-
tive effects for all strains (VarP[a] = 53.2%, MIP[a] ’ 1),
with clear separation between activity-reducing effects of
AJ, 129S1, and NZO and activity-increasing effects of B6,
NOD, and CAST (File S1). The inbred state induced an ad-
ditional activity-reducing effect for 129S1 and an activity-
increasing effect for NOD and WSB (VarP[b] = 8.9%, MIP
[b] ’ 0.8). Model selection suggested decisive evidence for
both symmetric and asymmetric epistasis (MIP[v] = 1, MIP
[w] ’ 1); but the percentage of variance contributed may be
relatively small (VarP[v] = 3.27%, VarP[w] = 3.86%). HPD
intervals for these types of epistasis included strong positive
(activity-increasing) departures from zero induced by the
(nonreciprocal) pairings 129S1 3 AJ and NZO 3 B6. A
small but well-supported overall effect of OFA was contrib-
uted by sex (VarP[S] = 1.7%, MIP[S] ’ 1), but sex-specific
effects of genetics or parent of origin were negligible.
EPS and PPI also showed decisive evidence of symmetric
epistasis (i.e., strain-pair effects that are reflected in the di-
agonal; MIP[v] = 1). In EPS this was accompanied by de-
cisive evidence of asymmetric epistasis (MIP[w] ’ 1) but,
despite a strong overall effect of sex, little evidence of
sex-specific strain differences. In PPI, symmetric epistasis
(VarP[v] = 23.7%) explained almost as much as additive
genetics (VarP[a] = 26.1%). PPI seemed to be driven by
effects of NZO (+0.5 additive effect to model) and NOD
(20.5 additive), with the most significant epistatic effects
coming from NOD crossed with B6 and 129S1 (File S1). A
similar effect was seen in EPS, where NZO contributes
a +1.5 effect, with NOD being significantly different from
zero but only at a 20.5 level. For both EPS and PPI, the
NZO 3 AJ cross appeared to contribute most significantly
to symmetric and asymmetric epistasis. We investigated to
what extent this could be explained through an effect of
body weight, which itself is affected by NZO. In the case of
PPI, when body weight is added as a covariate to the Bayes-
Diallel model, the contributions of NZO disappear (al-
though the strong NOD contribution remains). In the
case of EPS, however, adding weight to the model does
Figure 8 Straw plot of strain effects on (A) post-treatment and (B) drug response phenotypes. For each phenotype (x-axis), colored lines indicate
posterior means of strain-specific contributions relevant to each effect class (y-axis). The top three classes are effects constant among all strains,
corresponding to being female, inbred, and a female inbred; the middle five classes are effects that differ by strain; and the bottom two classes are
(posterior) predictive means for male and female inbreds, based on the model. For ease of comparison across phenotypes, x-axes are scaled to the SD of
each transformed phenotype. Some values are extreme enough to escape the 2 SD limits of the plot. For each straw plot, a higher posterior mean
indicates a higher drug level (brain, plasma), a greater therapeutic response (PPI), or a more severe adverse drug reaction (VCM, EPS, OFA), as indicated
by the scale under each plot.
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little to diminish the NZO effect (File S1). Body weight was
thus seen to be a strong predictor in the PPI phenotype,
albeit confounded with other genetic contributions, but not
of EPS. Body weight was also not a strong predictor of
baseline OFA. See File S1 for weight-adjusted results on
all baseline phenotypes.
VCM was explained the least well by the diallel effects,
with variance due to noise estimated at 60% (Table 5).
Nonetheless, we conclude with confidence that VCM is at
least 30% heritable, with nonzero contributions to the var-
iance due in largest part to aggregated effects of parent of
origin and symmetric epistasis.
Diallel effects on post-treatment drug levels: Levels of
haloperidol in plasma and brain were moderately correlated
overall (r = 0.5, P , 1026; transformations applied) but
showed evidence of distinct genetic architectures (Figure 5
and Figure 8). Diallel effects predicted78% of the variance
for plasma HAL (VarP[total] = 68–87% in Table 6) but
a much smaller and less certain 24% of brain HAL (VarP
[total] = 8.6–42.3%).
In plasma HAL, a powerful additive genetic effect (VarP
[a] ’ 20%, MIP[a] = 0.97) was largely driven by NZO. NZO
appeared to increase the plasma drug levels of any strain it
was crossed with, particularly when inherited through the
maternal line (VarP[m] ’ 9%, MIP[m] = 0.043), as indi-
cated by the strong banding pattern in Figure 9, A and B,
and the HPD intervals in Figure 9C. An additive decreasing
effect on plasma HAL was exerted by B6 (Figure 9C). The
additive effects of NZO and B6 are consistent with our pre-
vious report (Crowley et al. 2012a) in which, following
chronic haloperidol treatment, drug levels were much lower
in B6 (12 6 2 nM) than in NZO (62 6 8 nM; P , 0.001).
Our estimates of symmetric epistasis (VarP[v] = 14.6%, MIP
[v] = 0.22; File S1) indicate that regardless of parent-of-
origin descent, plasma HAL tends to be lower for hybrids of
PWK and NOD and high for hybrids of WSB and PWK. The
sex-specific effects show that, overall or in each strain, there
was little difference between males and females.
Brain haloperidol concentrations were reduced by addi-
tive effects of B6 and NOD, increased by additive effects of
CAST and PWK, and generally increased in inbreds (see File
S1). Other genetic effects failed to show strong deviations
from zero, and model selection provided little evidence for
or against most types of effects, suggesting a low signal-to-
noise ratio in this phenotype.
Diallel effects on drug response: For each behavioral
measure, drug response was estimated as the increase in
the pre- to post-treatment phenotype (i.e., gain score) asso-
ciated with drug treatment less that seen for placebo treat-
ment (see Table 2 and Statistical Models and Methods). To
these estimates of drug response we applied the BayesDiallel
model, generating posterior intervals for effects of genetics,
parent of origin, and sex (as in Figure 11). Estimation of
diallel effects on drug response was performed using two
different approaches: DoM and MIMP (see Statistical Models
and Methods for more details). In analyses for which both
were applicable, we obtained almost indistinguishable
results. For this reason and reasons described below, we
predominantly report results from the MIMP estimator and
use DoM estimates only for special cases, such as analyses
adjusting for body weight. All variations of the analyses are
available, however, in File S1.
The MIMP and DoM estimators rely on different assump-
tions and make different trade-offs: the MIMP estimator
controls for cage effects but uses only a subset of data at any
one time; the DoM does not control for cage, but uses all of
the data at once. The fact that they give nearly identical
results reveals something about the effects present in these
particular data. In our experiment, mouse numbers for
different conditions were nearly balanced, and our design
ensured that mice in the same diallel category were housed
in the same cage for both drug and placebo treatments. The
Table 6 Diallel variance projection (VarP) for post-treatment phenotypes and treatment response variance projection (TReVarP)
for drug-response phenotypes







Overall inbreeding (B) 1.86 (0.00, 5.15) 0.34 (0.00, 1.23) 0.60 (0.00, 2.35) 1.46 (0.00, 4.28) 1.04 (0.00, 3.83) 2.17 (0.00, 7.35)
Overall sex (S) 1.01 (20.07, 3.65) 0.73 (20.04, 2.30) 0.71 (20.13, 2.70) 0.61 (20.29, 2.63) 0.63 (20.35, 2.77) 1.53 (20.33, 6.08)
Overall sex 3 inbreeding (BS) 0.32 (20.14, 1.43) 0.23 (20.11, 0.98) 0.66 (20.12, 2.54) 3.02 (20.02, 6.89) 2.58 (20.12, 7.73) 2.05 (20.29, 6.60)
Additive (a) 14.34 (2.71, 26.85) 19.73 (9.42, 30.44) 28.01 (13.85, 42.85) 5.36 (20.76, 14.65) 7.51 (0.19, 16.55) 5.65 (20.35, 14.98)
Inbreeding (b) 0.41 (20.65, 2.60) 2.81 (20.76, 6.72) 0.99 (21.37, 4.45) 12.82 (1.24, 22.73) 2.64 (20.61, 8.50) 3.47 (20.49, 11.96)
Parent of origin (m) 0.36 (20.03, 1.60) 8.81 (2.74, 15.46) 14.81 (0.01, 31.53) 0.74 (-0.11, 2.66) 5.34 (20.22, 13.72) 7.36 (20.03, 18.98)
Symmetric epistasis (v) 3.94 (20.83, 19.94) 14.58 (6.56, 23.42) 6.11 (21.09, 17.36) 5.86 (20.45, 19.16) 13.96 (0.44, 27.57) 6.69 (0.15, 17.67)
Asymmetric epistasis (w) 0.37 (20.06, 1.54) 6.92 (1.37, 12.43) 9.73 (20.54, 25.85) 0.78 (20.11, 3.24) 12.22 (0.33, 25.84) 8.47 (20.15, 21.42)
Sex 3 additive (aS) 0.54 (20.04, 3.31) 4.07 (0.42, 8.07) 1.15 (20.06, 3.14) 1.36 (20.05, 5.32) 4.34 (0.03, 9.69) 3.36 (20.04, 9.16)
Sex 3 inbreeding (bS) 0.03 (20.04, 0.12) 0.82 (20.37, 2.52) 0.33 (20.11, 1.24) 0.17 (20.13, 0.90) 3.63 (20.26, 12.01) 0.85 (20.24, 3.29)
Sex 3 parent of origin (mS) 0.34 (20.01, 1.77) 2.95 (20.11, 6.49) 1.28 (20.07, 3.42) 0.41 (20.04, 1.68) 2.27 (20.09, 5.81) 5.74 (0.03, 15.01)
Sex 3 symmetric epistasis (vS) 0.41 (20.13, 2.18) 7.76 (2.35, 13.45) 1.34 (0.01, 3.85) 0.42 (20.14, 2.03) 2.50 (20.05, 6.97) 3.00 (20.06, 8.55)
Sex 3 asymmetric epistasis (wS) 0.08 (20.05, 0.46) 7.80 (3.07, 13.26) 1.89 (20.03, 5.77) 0.46 (20.07, 2.07) 3.16 (0.04, 8.79) 4.09 (20.24, 12.07)
Total variance explained 24.02 (8.62, 42.30) 77.52 (68.19, 86.71) 67.62 (50.92, 83.69) 33.47 (16.26, 51.37) 61.80 (39.75, 82.66) 54.45 (35.12, 75.24)
Unexplained variance 75.98 (57.70, 91.38) 22.48 (13.29, 31.81) 32.38 (16.31, 49.08) 66.53 (48.63, 83.74) 38.20 (17.34, 60.25) 45.55 (24.76, 64.88)
For each phenotype (column) is listed the predicted percentages, along with 95% credibility intervals, of variance that would be attributable to each class of effect in a future
complete diallel of the same parental strains.
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similarity between the credibility intervals of MIMP and
DoM suggests that variance due to cage effects does not
inflate uncertainty in the DoM estimator and is consistent
with such cage effects being negligible—or at least that the
DoM estimator’s reduced bias balances the MIMP estimator’s
reduced variability.
The contributions of each inheritance class to drug
response are summarized in Table 6. We term this decom-
position the diallel TReVarP because it predicts based on the
observed data how much each class of effect would influ-
ence drug response in a perfectly balanced, complete, future
diallel. These contributions are further summarized as ag-
gregated classes in Figure 5B. The results of model selection,
applied to drug response via the MIMP estimator, are sum-
marized in Figure 10 (last four columns).
Haloperidol caused high levels of rigidity (EPS; reduced
latency to move on inclined screen) in mice inheriting
genomic material from NZO and 129S1, with some evidence
for this effect being more potent when inheritance is trans-
mitted through the mother (horizontal banding in Figure
12A; additive and maternal effects in Figure 8 and Figure
11). The wild-derived strains CAST, PWK, and to a lesser
extent WSB, by contrast, contributed additively to a resistance
phenotype (Figure 11). In all, diallel effects on EPS haloper-
idol response predicted 68% of the variance in treatment
effect (Figure 5), with this split largely among three classes:
additive genetics (posterior mean TReVarP[a] = 28% in
Table 6; MIP[a] = 1 in Figure 10), parent of origin (TReVarP
[m] = 14.8%; MIP[m]’ 0.7), and asymmetric epistasis (a type
of parent-of-origin effect; TReVarP[w] = 9.7%, MIP[w] =
0.65). Inbreeding and sex contributed negligibly (Figure 10
and Figure 11), with strong evidence against their overall
effects (MIP[S] = 0.02 and MIP[B] = 0.02) and positive
evidence against their interaction (MIP[BS] = 0.05).
It is interesting to note that NZO and 129S1, the two
strains shown to have positive additive effects on haloperidol
Figure 9 Diallel effects on haloperidol drug concentration in plasma following chronic treatment. A and B, respectively, show observed and predicted
means for plasma HAL in each diallel category. Shading reports haloperidol concentration (nM) on the log scale from 2.49 (open squares) to 4.34 (solid
squares). “X” marks in A indicate missing data. Each square in B is the posterior predicted mean from fitting BayesDiallel to the data in A. C shows
highest posterior density (HPD) intervals for a subset of the diallel effects on post-treatment plasma drug levels (plasma HAL). D shows the same subset
of effects as estimated when including weight (“pre.centered.wt”) among the fixed covariates.
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levels, experienced the greatest increase in EPS following
chronic treatment. This observation is supported by the
significant overall positive correlation between plasma HAL
and EPS (r = 0.21, P = 0.017 for predrug EPS; r = 0.275,
P = 0.013 for postdrug EPS) and is consistent with human
studies that show dose to be a major predictor of EPS lia-
bility (Hsin-Tung and Simpson 2000; Dayalu and Chou
2008). As described above, NZO strongly affects pretreat-
ment weight, and weight significantly predicts drug levels
after chronic treatment. The relationship between body
weight genetics and EPS haloperidol response is therefore
likely to be complex, and our design does not provide a basis
for the explicit weight matching that would clarify this mat-
ter. Nonetheless, in File S1, we report a DoM analysis that
includes body weight as a covariate: this produces wider
intervals, reduces the effect of NZO, but mostly retains ad-
ditive and maternal effects of 129S1. This weight-adjusted
analysis requires careful interpretation (see Body weight as
a covariate below), but its result is consistent with the ef-
fects of 129S1 and weight on drug response being relatively
independent.
Diallel effects on locomotor activity (OFA) in response to
haloperidol contrasted primarily among different strains of
inbreds (posterior mean TReVarP[b] = 12.8% in Table 6;
MIP[b] = 0.56 in Figure 10). This contrast was driven
mostly by the 129S1 inbreds being most sensitive to drug-
induced reduction in OFA and the WSB inbreds being most
resistant (Figure 8). Specifically, in response to drug, the
129S1 inbreds reduced OFA more than would be expected
based on additive effects (Figure 12 and Figure 13),
whereas the WSB inbred was marginally more resistant than
expected (Figure 12 and Figure 13). Across all inbreds, ac-
tivity in response to drug reduced more in males than in
females (female.inbreed estimate in Figure 13; bottom two
categories in OFA part of Figure 8; MIP[BS] = 0.65). We
found little evidence for or against diallel effects unrelated
to inbreeding (e.g., Figure 5, where inbreeding is catego-
rized within epistasis).
Undersampling of PPI and VCM measurements (i.e., too
few mice measured post-treatment) makes estimation of di-
allel effects on drug response for these phenotypes relatively
imprecise. For PPI, diallel effects predicted 40–83% of the
variance in drug response (posterior mean TReVarP[total] =
61.8%; Table 6); for VCM, they predicted 35–75% (TReVarP
[total] = 54.5%). For PPI drug response, we could not rule
out either symmetric epistasis (TReVarP[v] = 0.44–27.57%;
MIP[v] = 0.45) or asymmetric epistasis (TReVarP[w] =
0.33–25%; MIP[w] = 0.51), but found strong evidence
against overall effects of both sex (MIP[S] = 0.012) and
inbreeding (MIP[B] = 0.024). Some combinations of effects
were well informed: compared with other diallel categories,
PPI was strongly reduced in inbred B6 females (Figure 8).
HPDs for diallel effects from the MIMP estimator (File S1)
mostly settle around zero, but there is a weak pattern of B6
epistasis with other strains (including PWK, NZO, and
WSB). MIMP analysis of drug effect on VCM showed strong
evidence against an overall effect of sex (MIP[S] = 0.013)
but otherwise little evidence for or against other diallel ef-
fect groups.
Body weight as a covariate
The eight CC parental strains demonstrate about a fourfold
range in body weight, with the three wild-derived strains
being the lightest and NZO by far the heaviest. Since NZO
had such high additive dosage effects on plasma HAL, we
decided to take a closer look at the relationship between
(pretreatment) body weight and all other phenotypes. As
shown in Figure 14, body weight correlates positively with
plasma HAL (r = 0.17, P , 0.046). For OFA, the picture is
more complex: weight is negatively correlated with pretreat-
ment OFA (r= 20.37, P, 13 1026), negatively correlated
with gain postdrug (r = 20.38, P = 0.00011), but un-
correlated with gain post-placebo (r = 20.01, P =
0.89). Similarly, weight is positively correlated with
EPS pretreatment (r = 0.42, P , 1026) and gain post-
drug (r = 0.46, P = 3.6 3 1026), but uncorrelated with
gain post-placebo (r = 20.03, P = 0.76). A correlation
between body weight and drug response does not indi-
cate causation because genetic effects on the two cannot
be disentangled. Nonetheless, we may still use weight as
a covariate in diallel analysis to support hypothesis test-
ing. As shown in Figure 9D, adding weight as a covariate
for plasma HAL diminishes the additive and maternal
effects of the heaviest strain, NZO, but does not diminish
the concentration-lowering effect of B6. In File S1, we pres-
ent HPD plots with and without body weight as a covariate
for all analyses (except MIMP, for which weight adjust-
ment outside of the matching procedure itself would be
inappropriate). DoM analyses of drug response showed
that in EPS weight was confounded primarily with effects
Figure 10 Model inclusion probabilities (MIP) of diallel
effect classes for post-treatment and drug response
phenotypes using multiple-impute matched pairs (MIMP).
MIPs near 1 (red) indicate strong evidence for a contri-
bution to the phenotype, MIPs near 0 (blue) indicate
evidence of negligible or zero contribution, and MIPs
near 0.5 indicate that the data provide little evidence
for or against inclusion.
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attributed to NZO and that weight adjustment in OFA did
not alter the clear (non-NZO driven) pattern of strain-specific
inbreeding effects described above.
Discussion
We have used a quantitative genetics approach, applying
causal reasoning to an existing Bayesian hierarchical model,
to estimate genetic, parent-of-origin and sex-specific effects
on haloperidol-induced adverse drug reactions in the founder
mouse strains of the Collaborative Cross and their F1 hy-
brids. Through a large diallel, we generated offspring whose
response to haloperidol treatment showed substantial het-
erogeneity. By examining behavioral phenotypes before and
after treatment in both drug and placebo groups, we were
able to separate diallel effects on behavior from diallel ef-
fects on behavioral response to drug. We could thus estimate
drug response (or treatment effect) as the response specifi-
cally induced by haloperidol and not by other factors con-
comitant with treatment. In doing so we found evidence that
baseline and drug response phenotypes have distinct genetic
architectures.
Our most informed drug response phenotypes, EPS and
OFA, showed contrasting patterns of diallel effects. For EPS
drug response, the 70% of explained variance could be
mostly attributed to additive genetics and parent of origin.
Severity of EPS following acute treatment was strongly in-
creased by additive genomic contributions of NZO and
129S1, with evidence of 129S1’s effect being stronger still
when inherited through the maternal line; it was decreased
by additive contributions from the wild-derived strains
CAST, PWK, and WSB. This separation of effects among
the strains could mean a relatively small number of variants
explaining a relatively large amount of variance and moti-
vates future mapping studies.
For OFA drug response, by contrast, we found evidence
against substantive effects of additive genetics. We instead
found evidence for an effect of inbreeding, especially in
males. Indeed, the 129S1 inbred was particularly susceptible
to the activity-lowering effects of haloperidol, an observation
consistent with recessivity or canalizing epistasis, whereby
potentially multiple haplotypes in the 129S1 genome that
would otherwise induce susceptibility are neutralized when
combined in an F1 hybrid with other CC strains. This too
Figure 11 HPD intervals of diallel effects on the treatment effect of haloperidol for rigidity on the inclined screen (EPS). Estimates are from the multiply
impute matched pair (MIMP) method. Symbols and parameter definitions are as in Figure 7. The plot shows that an increased genomic contribution of
129S1 or NZO from either parent (additive effects), and especially an increased genomic contribution of 129S1 from the mother line (maternal effects),
leads to an increase in EPS in response to drug (see also Figure 12A).
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suggests potential value in follow-up mapping studies, e.g.,
backcrossing 129S1 with other strains.
For baseline behavioral phenotypes, our results show
strong to decisive evidence of additive genetics and epistasis,
with nonreciprocal epistatic interactions making an especially
large relative contribution to prepulse inhibition (23.7% of
the predicted variance). To our knowledge, this is the first
time EPS, PPI, or VCM has been studied in a diallel. Our
results for baseline OFA provide an overdue update to older
work on activity in inbred diallels (e.g., Henderson 1967;
Halcomb et al. 1975; Crusio et al. 1984), and our finding that
baseline and drug-response OFAs have distinct genetic archi-
tectures is in line with much earlier diallel studies on OFA
response to amphetamine (Anisman 1976; Kitahama and
Valatx 1979) and nicotine (Marks et al. 1986). Our finding
of pervasive epistasis, at least among behavioral phenotypes,
is in line with that recently described for other model organ-
isms (e.g., Zwarts et al. 2011; Huang et al. 2012).
In general, behavior and behavioral responses to halo-
peridol were explained only in part by additive or domi-
nance genetics and usually had a substantial contribution of
more complex effects and unexplained variance. This is in
line with the most recent data for human complex traits
(Purcell et al. 2009; Lander 2011; Visscher et al. 2012),
where many genes contribute individually small, but collec-
tively large, effects to the phenotype; it also helps explain
the difficulty thus far in identifying genes with major effects
on haloperidol-induced ADR in relatively small studies on
humans (Åberg et al. 2010) and mice (Crowley et al.
2012b). As with many complex diseases, identifying suscep-
tibility genes for haloperidol-induced ADR in humans will
require sample sizes that are very large (.5000). Nonethe-
less, we show that the heritabilities of these ADRs are sim-
ilar to those of many other clinical phenotypes that have
been highly successful in GWAS (i.e., diabetes, obesity,
Crohn’s disease, and schizophrenia). As with these other
phenotypes, it will be critical to design a human study that
is not only large but also mindful of the trait’s genetic
architecture.
Among the most pronounced strain effects in this study
was the observation that, compared with the other mouse
strains or F1 hybrids, NZO and NZO-descended mice have
higher steady-state levels of plasma haloperidol. The results
of our covariate analysis suggest that these effects are likely
confounded by body weight and adiposity. As part of our
experimental design haloperidol dosage was calibrated to
body weight; but it is possible that more careful calibration
is needed for mice with considerable NZO descent. On the
other hand, brain levels of haloperidol in NZO mice are not
that different from those in other strains, suggesting that the
dosage may be adequate for psychological studies. At the
opposite end of the spectrum, unusually low levels of halo-
peridol in plasma were seen in B6 mice, yet these mice still
showed a significant drop in activity. Haloperidol seems,
therefore, to trigger a more adverse reaction in mice with
B6 descent, possibly because the drug is processed more
quickly than in other individuals. Further experiments with
B6 should note that this strain’s reaction to haloperidol cor-
responds to a significantly more negative additive effect
atreatB6 in OFA than for other CC parental strains.
Our diallel study suggests three additional design factors,
beyond pure sample size, that will be important to consider
Figure 12 Predicted effects of sex-averaged diallel category on treatment effect of haloperidol for (A) inclined screen rigidity (EPS) and (B) open field
activity (OFA). Shading in each square represents the effect of haloperidol on the phenotype among mice of the indicated parentage, averaged for sex
and controlled for placebo effects using the multiply imputed matched pair (MIMP) method.
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for haloperidol pharmacogenomics studies. First, steady-state
drug levels must be collected. In mice, we have maximal
control over dosing and are assured of treatment compli-
ance; in humans, neither of these is true. To exploit this,
drug levels should be measured in all subjects and con-
sidered a primary covariate. Second, drug-response phe-
notypes must be rigorously defined. Haloperidol-induced
ADRs come in a variety of forms, from Parkinsonian tremor
to uncontrolled jaw movements. In this study, we collected
only a sample of possible ADR-related motor phenotypes
but found that the patterns of genetic effects among them
differed. Therefore, meaningful genetic results will require
accurate diagnosis and quantification of haloperidol ADRs
with high interrater reliability. Third, body weight is a
meaningful covariate that should be collected. Regardless
of how it exerts its effect, be it through pharmacokinetics,
pharmacodynamics, or otherwise, body weight is too easy
to measure to be ignored.
Our experiment examines treatment effect heterogeneity
by estimating the effects of causes that were knowingly
applied. Investigating HTE in humans, by contrast, typically
starts with a search for potential causes of observed effects.
Dissection of HTE in clinical trials has been characterized as
“an experiment and a survey rolled into one” (Kravitz et al.
2004, p. 667, paraphrasing Longford and Nelder 1999):
randomization may be present at the level of treatment assign-
ment, but genetics, the open-textured effects of environment,
and interactions between the two represent unavoidable
confounds. Statistical methods to analyze HTE in humans,
in particular “subset” or “subgroup” analysis, must therefore
navigate treacherous waters, taking pains to avoid, for ex-
ample, data dredging through selective analyses that fail
to account for multiplicity (Byar 1985; Kravitz et al. 2004;
Rothwell 2005; Willke et al. 2012). Bayesian hierarchical
models that induce shrinkage have found application in this
context (Dixon and Simon 1991; Bayman et al. 2010). We
too benefit from Bayesian shrinkage (Lenarcic et al. 2012),
but also draw considerably greater strength from experi-
mental design. By using a matched drug–placebo design
and limiting our attention to a closed set of knowingly var-
ied primary factors (genetics, parent of origin, and sex), we
can work on the (in our view) realistic premise that the
effects of these factors (e.g., the effect of switching genetic
descent between parents) may be small but are unlikely to
Figure 13 Highest posterior density intervals of diallel effects on the treatment effect of haloperidol for open field activity. Estimates are from the
multiply imputed matched pair (MIMP) method. Symbols and parameter definitions are as in Figure 7. See Figure 12B for predicted effects of drug
response on OFA based on these parameters.
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be exactly zero. This allows us to focus exclusively on robust
joint estimation. To provide a complementary perspective, in
our model selection analysis we entertain inference under
the premise that such zero effects do have substantial prior
probability.
Previously we developed a detailed decomposition of
diallel inheritance and a reliable Bayesian hierarchical
model for analyzing univariate quantitative phenotypes
(Lenarcic et al. 2012). But a new methodology was required
to measure the interaction between diallel effects and the
effect of drug exposure. Motivated by the Neyman–Rubin
potential outcomes framework (Rubin 2005), we have pro-
posed to measure the many components of interaction
between drug and inheritance as the difference between
drug-treated and placebo-treated model coefficients. We
have demonstrated two methods for estimating this genetic
3 treatment vector: difference of models and multiple-
impute matched pairs. Both estimation techniques can po-
tentially be extended to other experimental designs that
vary genetics for both placebo and drug. Our variance
projection statistic, computing the difference in variation
structure between experimental samples in future popula-
tions, is a flexible breakdown that can serve as an alternative
to broad-sense heritability; in TreVarP we extend the con-
cept naturally to summarizing how heritable factors affect
drug response.
Heritable effects inferred from a diallel of the Collabora-
tive Cross founders can be more or less presumed to exist in
the CC and Diversity Outbred populations. They can also
help guide design of follow-up experiments in those re-
sources: for example, strong parent-of-origin epistasis sug-
gests an advantage of reciprocally intercrossing CC lines (i.e.,
to form a recombinant inbred intercross, or CC-RIX), whereas
strong additivity and epistasis but no parent-of-origin effects
suggests more immediate value in designs using the CC and
DO directly.
We demonstrate here that a randomized-treatment study
on the experimental diallel not only confirms a treatment
effect but also estimates higher-order genetic-by-treatment
interactions. Those interactions would be impossible to
discover in an observational study where genetics might
have influenced who got treatment and/or where the
genetic variation in the population may be poorly aligned
for discovering interactions. Our approach to defining and
inferring genetic–drug interplay provides a starting point—
not only for more sophisticated modeling that explicitly tar-
gets causality parameters, but also for prospective studies in
mouse and humans that dissect the genetic architecture of
adverse reactions of drugs in general and haloperidol in
particular.
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Appendix A
Constrained Priors for Diallel Effects
Although the BayesDiallel model is inherently overspecified, some identifiability can be recovered through the use of
constrained priors, as in Equation 15. Fixing the sum of all additive effects to zero ensures that marginal HPD intervals on
single coefficients can be used to identify significant differences of interest, for example, whether aB6 2 aCAST . 0. We
achieve this constraint using a J 3 (J 2 1) contrast matrix
M ¼
266664
c 2 k . . . 2 k
2 k c . . . 2 k
. . . . . . . . . . . .
2 k . . . 2 k c
2m 2m 2m 2m
377775  ; (A1)
where m ¼ 1= ffiffiffiffiffiffiffiffiffiffiffiJ21p ;  k ¼ ð2 1þ ffiffiJp ÞðJ21Þ23=2;  and c ¼ ðn2 2Þkþm: This allows transformations of the form a ¼ M~a;
where a is the original coefficient set for additive effects, and ~a is the postulated set of i.i.d. centered coefficients. Letting Xa
be the n 3 J design matrix corresponding to the original additive a1, a2, . . . , aJ coefficients, then applying the transformation
yields the n 3 (J 2 1) matrix X~a ¼ XaM: In this case all J 2 1 coefficients ~a defined on the transformed space have an i.i.d.
marginal prior distribution Nð0; t2aÞ: All J coefficients in the original space also have a marginal Nð0; t2aÞ distribution, but they








Simulations for Treatment Response Variability
Reflecting the simulations in Table 4, in Table B1 we investigated coverage and width for credibility intervals estimating
contributions to variance in treatment response. Simulated variance contributions were a = 42.6, fa = 7.7, m = 42.6, and
s2 = 7.1. At the 95% level, with sample size 115, for the true effects we see that HPD intervals have approximately a width of
#15. On average, frequency coverage of all effects was high and greater than the purported HPD coverage. However, there
appeared to be a systematic undercoverage of the noise contribution, due to fitting a large complete model with symmetric
and asymmetric effects, even though the only nonadditive contribution in this simulation is noise. We reason that this
approach has a potential to overestimate whole-model contribution when the whole model is too large, but that individual
effects are nonetheless robustly covered.
Table B1 Frequency coverage of the true values by MP judged in simulation
Diallel effect 50% 90% 95% 99%
a 42.5 [5.1] 87.4 [12.5] 93.7 [15] 99.6 [19.7]
fa 67.3 [2.8] 98.4 [6.8] 99.2 [8.1] 100 [10.6]
m 19.7 [4.8] 68.5 [11.8] 85.8 [14.1] 98.4 [18.6]
bfemale 99.6 [0.1] 100 [0.6] 100 [0.8] 100 [1.3]
fm 0.8 [0.4] 96.9 [1.1] 99.6 [1.3] 100 [1.9]
b 99.2 [0.7] 100 [1.9] 100 [2.5] 100 [4.1]
fb 100 [0.3] 100 [0.9] 100 [1.2] 100 [2.1]
v 94.1 [1.3] 100 [2.7] 100 [3.3] 100 [4.5]
fv 55.9 [0.7] 100 [1.5] 100 [1.8] 100 [2.5]
w 86.6 [1.5] 100 [3.1] 100 [3.8] 100 [5.2]
fw 0 [0.4] 76.4 [1.1] 96.1 [1.4] 99.6 [2]
s2 19.3 [1.6] 58.7 [4] 70.9 [4.8] 88.2 [6.4]
Realized frequency coverage of the truth, and average width [in brackets], is given for estimated credibility intervals of TReVarP in 400 simulations. Coverage was examined
for HPD intervals containing 50%, 90%, 95%, and 99% of the posterior. In this simulation, only a, m, and fa had nonzero contributions to treatment effect variability.
Credibility intervals appear to have realistic coverage of the truth, although they tend to undercover the noise of s2 contribution—likely due to the true model being a subset
of the full model.
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Appendix C
Theoretical Comparison of Difference of Models and Matched Pairs Estimators
DoM and MP procedures are compared in terms of their bias and variance. This comparison is made in regard to estimation
of a single set of grouped effects b inferred under Bayesian (or ridge) priors that, in aiming to reduce overall L2 error, shrink
those effects toward zero. For the MP estimator, parameter vector bMP is shrunk to zero by a single dispersion parameter
t2drug2placebo; for the DoM estimator, both b
drug and bplacebo are shrunk to zero separately by dispersions t2drug and t
2
placebo:

















placebo: Following Theobald (1974),


























































Let XTXþ ððs2drug þ s2placeboÞ=t2drug2placeboÞI[A and note that for any invertible matrix A and perturbation matrix P, (A +






where ddrug ¼ s2drug=t2drug 2 ðs2drug þ s2 placeboÞ=t2drug2placebo; and dplacebo ¼ s2placebo=t2placebo 2 ðs2drug þ s2placeboÞ=t2drug2placebo: Thus
the MP estimator has less variability, as long as t2drug parameters are large and the match dispersion t
2
drug2placebo is smaller. The MP
















































and the reduced squared bias of the DoM estimator is o(A22), such that DoM is potentially advantageous when matching




drug2drug are all large, the two estimators are
equivalent.
In Figure C1, we keep bdrugj fixed at 1 and vary b
placebo
j from 21 to 1. Fixing s
2
drug ¼ s2placebo ¼ 1 and using




ij ¼ 50: The MP outperforms
DoM when differences bdrugj 2b
placebo
j are large or ðbplaceboj Þ2 is small. When bdrugj 2bplaceboj is small, DoM is preferable, but if
s2placebo is also small, then it is actually preferable to use the MP. Thus we conclude that both DoM and MP priors and
346 J. J. Crowley et al.
estimators have data settings where one outperforms the other in terms of MSE. The DoM estimator allows for more
straightforward modeling of additional unmatchable covariates and is easier to apply when matched pairs are difficult to
select or impute.
Figure C1 Theoretical squared bias of DoM and MP esti-
mators, keeping bdrugj fixed and varying b
placebo
j :
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Chapter 1
Summaries for all phenotypes
1.1 Pre-drug phenotypes
Table 1.1: Model inclusion probabilities (MIPs) for pre-treatment phenotypes
Diallel effect Body Weight EPSpre OFApre PPIpre VCMpre
Overall inbreeding (B) 0.999 0.005 0.809 0.002 0.005
Overall sex (S) 0.999 0.055 0.999 0.999 0.009
Overall sex × inbreeding (BS) 0.001 0.005 0.068 0.005 0.035
Additive (a) 1.000 1.000 1.000 1.000 0.940
Inbreeding (b) 0.001 0.987 0.998 0.116 0.257
Parent of origin (m) 0.852 0.629 0.777 0.003 0.017
Symmetric epistasis (v) 0.001 0.999 1.000 1.000 0.832
Asymmetric epistasis (w) 0.147 0.949 0.999 0.016 0.055
Sex × additive (aS) 0.000 0.059 0.431 0.032 0.097
Sex × inbreeding (bS) 0.002 0.085 0.255 0.070 0.134
Sex × parent of origin (mS) 0.000 0.006 0.316 0.000 0.011
Sex × symmetric epistasis (vS) 0.000 0.073 0.316 0.083 0.032
Sex × asymmetric epistasis (wS) 0.000 0.025 0.276 0.001 0.042
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Table 1.2: diallel variance projection (VarP) for pre-treatment phenotypes (posterior medians and 95 percent credibility
intervals)
Diallel effect Body Weight EPSpre OFApre PPIpre VCMpre
Overall inbreeding (B)
1.17 0.12 0.64 0.13 0.52
(0.52, 1.85) (0.00, 0.45) (0.01, 1.33) (0.00, 0.46) (0.00, 2.09)
Overall sex (S)
13.75 0.75 1.65 6.02 0.65
(10.19, 17.00) (-0.00, 1.72) (0.48, 3.06) (3.05, 8.67) (-0.09, 2.56)
Overall sex × inbreeding (BS)
-0.22 0.04 0.10 0.31 0.42
(-0.51, 0.13) (-0.06, 0.23) (-0.10, 0.41) (-0.23, 0.99) (-0.13, 1.62)
Additive (a)
60.46 38.62 53.18 26.10 10.19
(45.75, 75.68) (27.13, 49.62) (43.68, 62.57) (13.54, 37.58) (1.41, 21.05)
Inbreeding (b)
0.37 10.14 8.85 1.35 2.93
(-3.31, 4.09) (4.02, 16.27) (4.73, 13.05) (-1.46, 3.97) (-0.48, 8.53)
Parent of origin (m)
4.31 3.09 1.39 2.38 4.49
(0.14, 9.24) (1.02, 5.55) (-0.04, 3.18) (-0.06, 4.97) (0.21, 10.36)
Symmetric epistasis (v)
4.99 5.86 3.27 23.71 7.19
(-6.26, 15.94) (-0.51, 12.89) (-1.65, 9.46) (14.03, 34.21) (1.12, 14.06)
Asymmetric epistasis (w)
2.93 3.79 3.86 3.00 3.58
(-0.72, 6.95) (1.25, 6.67) (1.50, 6.36) (0.55, 5.31) (0.34, 7.93)
Sex × additive (aS)
0.56 1.23 0.25 1.63 3.33
(-0.64, 1.78) (0.14, 2.50) (-0.03, 0.78) (0.06, 3.27) (0.10, 7.97)
Sex × inbreeding (bS)
0.33 0.35 0.04 0.50 0.75
(-0.19, 0.90) (-0.09, 0.95) (-0.02, 0.19) (-0.11, 1.26) (-0.30, 2.52)
Sex × parent of origin (mS)
0.64 0.72 0.22 0.88 2.47
(-0.47, 1.94) (0.03, 1.66) (-0.01, 0.68) (-0.07, 2.05) (0.12, 5.83)
Sex × symmetric epistasis (vS)
1.48 1.24 0.36 2.49 2.07
(0.23, 3.10) (0.31, 2.48) (-0.02, 1.33) (0.81, 4.33) (0.19, 4.48)
Sex × asymmetric epistasis (wS)
1.49 1.05 0.23 1.70 2.35
(-0.05, 3.20) (0.19, 2.08) (-0.02, 0.95) (0.40, 2.97) (0.25, 5.10)
Total variance explained
92.27 66.99 74.05 70.19 40.94
(90.60, 93.89) (62.18, 71.89) (70.50, 77.77) (65.80, 74.74) (29.04, 52.19)
Unexplained variance
7.73 33.01 25.95 29.81 59.06
(6.11, 9.40) (28.11, 37.82) (22.23, 29.50) (25.26, 34.20) (47.81, 70.96)
Table 1.3: Aggegrated diallel variance projection (VarP) for pre-treatment phenotypes (posterior medians and 95 percent
credibility intervals)
Inheritance type Body Weight EPSpre OFApre PPIpre VCMpre
Sex (S)
13.75 0.75 1.65 6.02 0.65
(10.19, 17.00) (-0.00, 1.72) (0.48, 3.06) (3.05, 8.67) (-0.09, 2.56)
Additive (a)
60.46 38.62 53.18 26.10 10.19
(45.75, 75.68) (27.13, 49.62) (43.68, 62.57) (13.54, 37.58) (1.41, 21.05)
Sex-specific additive (aS)
0.56 1.23 0.25 1.63 3.33
(-0.64, 1.78) (0.14, 2.50) (-0.03, 0.78) (0.06, 3.27) (0.10, 7.97)
Parent of origin (m + w)
7.24 6.88 5.25 5.38 8.07
(4.29, 10.88) (4.01, 10.09) (2.95, 7.92) (2.79, 8.15) (2.48, 15.45)
Epistasis§ (B + b + v)
6.52 16.13 12.76 25.19 10.64
(-8.69, 20.16) (5.31, 26.97) (4.13, 21.86) (12.84, 36.30) (2.43, 20.17)
Sex-specific parent of origin (mS + wS)
2.13 1.77 0.45 2.57 4.82
(0.85, 3.87) (0.73, 3.02) (0.04, 1.23) (1.14, 4.09) (1.21, 9.04)
Sex-specific epistasis§ (BS + bS + vS)
1.59 1.63 0.50 3.30 3.24
(0.11, 3.34) (0.45, 2.99) (-0.06, 1.49) (1.39, 5.55) (0.49, 6.51)
Total explained
92.27 66.99 74.05 70.19 40.94
(90.60, 93.89) (62.18, 71.89) (70.50, 77.77) (65.80, 74.74) (29.04, 52.19)
Unexplained variance
7.73 33.01 25.95 29.81 59.06
(6.11, 9.40) (28.11, 37.82) (22.23, 29.50) (25.26, 34.20) (47.81, 70.96)
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1.2 Post-drug phenotypes
Table 1.4: Model inclusion probabilities (MIPs) for post-treatment phenotypes
Diallel effect Brain HAL Plasma HAL
Overall inbreeding (B) 0.804 0.003
Overall sex (S) 0.218 0.003
Overall sex × inbreeding (BS) 0.307 0.005
Additive (a) 0.308 0.966
Inbreeding (b) 0.198 0.054
Parent of origin (m) 0.186 0.043
Symmetric epistasis (v) 0.181 0.217
Asymmetric epistasis (w) 0.230 0.003
Sex × additive (aS) 0.205 0.005
Sex × inbreeding (bS) 0.211 0.032
Sex × parent of origin (mS) 0.214 0.002
Sex × symmetric epistasis (vS) 0.203 0.052
Sex × asymmetric epistasis (wS) 0.171 0.017
Table 1.5: diallel variance projection (VarP) for post-treatment phenotypes (posterior medians and 95 percent credibility
intervals)
Diallel effect Brain HAL Plasma HAL
Overall inbreeding (B)
1.86 0.34
(0.00, 5.15) (0.00, 1.23)
Overall sex (S)
1.01 0.73
(-0.07, 3.65) (-0.04, 2.30)
Overall sex × inbreeding (BS)
0.32 0.23
(-0.14, 1.43) (-0.11, 0.98)
Additive (a)
14.34 19.73
(2.71, 26.85) (9.42, 30.44)
Inbreeding (b)
0.41 2.81
(-0.65, 2.60) (-0.76, 6.72)
Parent of origin (m)
0.36 8.81
(-0.03, 1.60) (2.74, 15.46)
Symmetric epistasis (v)
3.94 14.58
(-0.83, 19.94) (6.56, 23.42)
Asymmetric epistasis (w)
0.37 6.92
(-0.06, 1.54) (1.37, 12.43)
Sex × additive (aS)
0.54 4.07
(-0.04, 3.31) (0.42, 8.07)
Sex × inbreeding (bS)
0.03 0.82
(-0.04, 0.12) (-0.37, 2.52)
Sex × parent of origin (mS)
0.34 2.95
(-0.01, 1.77) (-0.11, 6.49)
Sex × symmetric epistasis (vS)
0.41 7.76
(-0.13, 2.18) (2.35, 13.45)
Sex × asymmetric epistasis (wS)
0.08 7.80
(-0.05, 0.46) (3.07, 13.26)
Total variance explained
24.02 77.52
(8.62, 42.30) (68.19, 86.71)
Unexplained variance
75.98 22.48
(57.70, 91.38) (13.29, 31.81)
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Table 1.6: Aggegrated diallel variance projection (VarP) for post-treatment phenotypes (posterior medians and 95 percent
credibility intervals)
Inheritance type Brain HAL Plasma HAL
Sex (S)
1.01 0.73
(-0.07, 3.65) (-0.04, 2.30)
Additive (a)
14.34 19.73
(2.71, 26.85) (9.42, 30.44)
Sex-specific additive (aS)
0.54 4.07
(-0.04, 3.31) (0.42, 8.07)
Parent of origin (m + w)
0.72 15.73
(0.01, 2.65) (10.17, 21.72)
Epistasis§ (B + b + v)
6.21 17.73
(-0.63, 22.09) (7.78, 28.52)
Sex-specific parent of origin (mS + wS)
0.43 10.74
(0.00, 1.89) (5.50, 16.54)
Sex-specific epistasis§ (BS + bS + vS)
0.77 8.80
(-0.19, 2.93) (3.06, 14.59)
Total explained
24.02 77.52
(8.62, 42.30) (68.19, 86.71)
Unexplained variance
75.98 22.48
(57.70, 91.38) (13.29, 31.81)
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1.3 Drug response (Matched Pairs analysis)
Table 1.7: Model inclusion probabilities (MIPs) for drug response (match pair) phenotypes







Overall inbreeding (B) 0.021 0.144 0.024 0.048
Overall sex (S) 0.021 0.085 0.012 0.013
Overall sex × inbreeding (BS) 0.049 0.563 0.094 0.075
Additive (a) 1.000 0.510 0.284 0.064
Inbreeding (b) 0.231 0.751 0.277 0.362
Parent of origin (m) 0.711 0.187 0.115 0.093
Symmetric epistasis (v) 0.352 0.231 0.451 0.119
Asymmetric epistasis (w) 0.647 0.198 0.506 0.246
Sex × additive (aS) 0.123 0.224 0.253 0.122
Sex × inbreeding (bS) 0.215 0.213 0.293 0.201
Sex × parent of origin (mS) 0.140 0.203 0.112 0.173
Sex × symmetric epistasis (vS) 0.185 0.212 0.148 0.142
Sex × asymmetric epistasis (wS) 0.241 0.207 0.154 0.176
Table 1.8: diallel variance projection (VarP) for drug response (match pair) phenotypes (posterior medians and 95 percent
credibility intervals)








0.60 1.46 1.04 2.17
(0.00, 2.35) (0.00, 4.28) (0.00, 3.83) (0.00, 7.35)
Overall sex (S)
0.71 0.61 0.63 1.53
(-0.13, 2.70) (-0.29, 2.63) (-0.35, 2.77) (-0.33, 6.08)
Overall sex × inbreeding (BS)
0.66 3.02 2.58 2.05
(-0.12, 2.54) (-0.02, 6.89) (-0.12, 7.73) (-0.29, 6.60)
Additive (a)
28.01 5.36 7.51 5.65
(13.85, 42.85) (-0.76, 14.65) (0.19, 16.55) (-0.35, 14.98)
Inbreeding (b)
0.99 12.82 2.64 3.47
(-1.37, 4.45) (1.24, 22.73) (-0.61, 8.50) (-0.49, 11.96)
Parent of origin (m)
14.81 0.74 5.34 7.36
(0.01, 31.53) (-0.11, 2.66) (-0.22, 13.72) (-0.03, 18.98)
Symmetric epistasis (v)
6.11 5.86 13.96 6.69
(-1.09, 17.36) (-0.45, 19.16) (0.44, 27.57) (0.15, 17.67)
Asymmetric epistasis (w)
9.73 0.78 12.22 8.47
(-0.54, 25.85) (-0.11, 3.24) (0.33, 25.84) (-0.15, 21.42)
Sex × additive (aS)
1.15 1.36 4.34 3.36
(-0.06, 3.14) (-0.05, 5.32) (0.03, 9.69) (-0.04, 9.16)
Sex × inbreeding (bS)
0.33 0.17 3.63 0.85
(-0.11, 1.24) (-0.13, 0.90) (-0.26, 12.01) (-0.24, 3.29)
Sex × parent of origin (mS)
1.28 0.41 2.27 5.74
(-0.07, 3.42) (-0.04, 1.68) (-0.09, 5.81) (0.03, 15.01)
Sex × symmetric epistasis (vS)
1.34 0.42 2.50 3.00
(0.01, 3.85) (-0.14, 2.03) (-0.05, 6.97) (-0.06, 8.55)
Sex × asymmetric epistasis (wS)
1.89 0.46 3.16 4.09
(-0.03, 5.77) (-0.07, 2.07) (0.04, 8.79) (-0.24, 12.07)
Total variance explained
67.62 33.47 61.80 54.45
(50.92, 83.69) (16.26, 51.37) (39.75, 82.66) (35.12, 75.24)
Unexplained variance
32.38 66.53 38.20 45.55
(16.31, 49.08) (48.63, 83.74) (17.34, 60.25) (24.76, 64.88)
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Table 1.9: Aggegrated diallel variance projection (VarP) for drug response (match pair) phenotypes (posterior medians and
95 percent credibility intervals)








0.71 0.61 0.63 1.53
(-0.13, 2.70) (-0.29, 2.63) (-0.35, 2.77) (-0.33, 6.08)
Additive (a)
28.01 5.36 7.51 5.65
(13.85, 42.85) (-0.76, 14.65) (0.19, 16.55) (-0.35, 14.98)
Sex-specific additive (aS)
1.15 1.36 4.34 3.36
(-0.06, 3.14) (-0.05, 5.32) (0.03, 9.69) (-0.04, 9.16)
Parent of origin (m + w)
24.54 1.52 17.56 15.83
(6.70, 41.36) (0.05, 4.68) (3.70, 32.31) (2.98, 31.46)
Epistasis§ (B + b + v)
7.70 20.14 17.63 12.34
(-0.75, 19.75) (4.58, 38.11) (2.54, 33.18) (1.18, 26.16)
Sex-specific parent of origin (mS + wS)
3.17 0.87 5.43 9.84
(0.41, 7.55) (0.02, 3.03) (0.74, 11.87) (1.46, 20.70)
Sex-specific epistasis§ (BS + bS + vS)
2.33 3.61 8.70 5.91
(0.17, 5.65) (0.04, 7.83) (0.48, 19.62) (0.42, 13.53)
Total explained
67.62 33.47 61.80 54.45
(50.92, 83.69) (16.26, 51.37) (39.75, 82.66) (35.12, 75.24)
Unexplained variance
32.38 66.53 38.20 45.55





2.1.1 Observed and predicted values
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2.1.2 Model selection MIPs
Table 2.1: Model inclusion probabilities (MIPs) for Body Weight
Diallel effect Body Weight
Overall inbreeding (B) 0.999
Overall sex (S) 0.999
Overall sex × inbreeding (BS) 0.001
Additive (a) 1.000
Inbreeding (b) 0.001
Parent of origin (m) 0.852
Symmetric epistasis (v) 0.001
Asymmetric epistasis (w) 0.147
Sex × additive (aS) 0.000
Sex × inbreeding (bS) 0.002
Sex × parent of origin (mS) 0.000
Sex × symmetric epistasis (vS) 0.000
Sex × asymmetric epistasis (wS) 0.000
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2.1.4 Straw plot of single-strain effects
Figure 2.3: Straw plot of single-strain effects and predicted homozygotes for Body Weight
2.1.5 Variance Projection
Table 2.2: diallel variance projection (VarP) for Body Weight (posterior medians and 95 percent credibility intervals)

























Sex × additive (aS)
0.56
(-0.64, 1.78)
Sex × inbreeding (bS)
0.33
(-0.19, 0.90)
Sex × parent of origin (mS)
0.64
(-0.47, 1.94)
Sex × symmetric epistasis (vS)
1.48
(0.23, 3.10)
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2.1.6 Variance Projection (aggregated)
Table 2.3: Aggegrated diallel variance projection (VarP) for Body Weight (posterior medians and 95 percent credibility
intervals)



















































1 2 3 4 5 6 7 8



























1 2 3 4 5 6 7 8









2.49 2.8 3.11 3.41 3.72 4.03 4.34
Figure 3.1: Plasma HAL observed and predicted phenotype values
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3.1.2 Model selection MIPs
Table 3.1: Model inclusion probabilities (MIPs) for Plasma HAL
Diallel effect Plasma HAL
Overall inbreeding (B) 0.003
Overall sex (S) 0.003
Overall sex × inbreeding (BS) 0.005
Additive (a) 0.966
Inbreeding (b) 0.054
Parent of origin (m) 0.043
Symmetric epistasis (v) 0.217
Asymmetric epistasis (w) 0.003
Sex × additive (aS) 0.005
Sex × inbreeding (bS) 0.032
Sex × parent of origin (mS) 0.002
Sex × symmetric epistasis (vS) 0.052
Sex × asymmetric epistasis (wS) 0.017
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Figure 3.2: Highest posterior density intervals of diallel effects for Plasma HAL
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3.1.4 Straw plot of single-strain effects
Figure 3.3: Straw plot of single-strain effects and predicted homozygotes for Plasma HAL
3.1.5 Variance Projection
Table 3.2: diallel variance projection (VarP) for Plasma HAL (posterior medians and 95 percent credibility intervals)

























Sex × additive (aS)
4.07
(0.42, 8.07)
Sex × inbreeding (bS)
0.82
(-0.37, 2.52)
Sex × parent of origin (mS)
2.95
(-0.11, 6.49)
Sex × symmetric epistasis (vS)
7.76
(2.35, 13.45)
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3.1.6 Variance Projection (aggregated)
Table 3.3: Aggegrated diallel variance projection (VarP) for Plasma HAL (posterior medians and 95 percent credibility
intervals)






























Figure 3.4: Plasma HAL observed phenotype values
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3.2.2 Model selection MIPs
Table 3.4: Model inclusion probabilities (MIPs) for Plasma HAL
Diallel effect Plasma HAL
Inbreeding (b) 0.398
Parent of origin (m) 0.386
Symmetric epistasis (v) 0.442
Asymmetric epistasis (w) 0.376
Sex × additive (aS) 0.376
Sex × inbreeding (bS) 0.382
Sex × parent of origin (mS) 0.376
Sex × symmetric epistasis (vS) 0.393
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Figure 3.5: Highest posterior density intervals of diallel effects for Plasma HAL
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3.2.4 Straw plot of single-strain effects
Figure 3.6: Straw plot of single-strain effects and predicted homozygotes for Plasma HAL
3.2.5 Variance Projection
Table 3.5: diallel variance projection (VarP) for Plasma HAL (posterior medians and 95 percent credibility intervals)

























Sex × additive (aS)
4.24
(0.46, 8.51)
Sex × inbreeding (bS)
0.80
(-0.37, 2.53)
Sex × parent of origin (mS)
2.90
(-0.00, 6.67)
Sex × symmetric epistasis (vS)
7.64
(2.41, 13.29)
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3.2.6 Variance Projection (aggregated)
Table 3.6: Aggegrated diallel variance projection (VarP) for Plasma HAL (posterior medians and 95 percent credibility
intervals)
































4.1.1 Observed and predicted values
Figure 4.1: Brain HAL observed and predicted phenotype values
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4.1.2 Model selection MIPs
Table 4.1: Model inclusion probabilities (MIPs) for Brain HAL
Diallel effect Brain HAL
Overall inbreeding (B) 0.804
Overall sex (S) 0.218
Overall sex × inbreeding (BS) 0.307
Additive (a) 0.308
Inbreeding (b) 0.198
Parent of origin (m) 0.186
Symmetric epistasis (v) 0.181
Asymmetric epistasis (w) 0.230
Sex × additive (aS) 0.205
Sex × inbreeding (bS) 0.211
Sex × parent of origin (mS) 0.214
Sex × symmetric epistasis (vS) 0.203
Sex × asymmetric epistasis (wS) 0.171
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Figure 4.2: Highest posterior density intervals of diallel effects for Brain HAL
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4.1.4 Straw plot of single-strain effects
Figure 4.3: Straw plot of single-strain effects and predicted homozygotes for Brain HAL
4.1.5 Variance Projection
Table 4.2: diallel variance projection (VarP) for Brain HAL (posterior medians and 95 percent credibility intervals)

























Sex × additive (aS)
0.54
(-0.04, 3.31)
Sex × inbreeding (bS)
0.03
(-0.04, 0.12)
Sex × parent of origin (mS)
0.34
(-0.01, 1.77)
Sex × symmetric epistasis (vS)
0.41
(-0.13, 2.18)
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4.1.6 Variance Projection (aggregated)
Table 4.3: Aggegrated diallel variance projection (VarP) for Brain HAL (posterior medians and 95 percent credibility intervals)






























Figure 4.4: Brain HAL observed phenotype values
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4.2.2 Model selection MIPs
Table 4.4: Model inclusion probabilities (MIPs) for Brain HAL
Diallel effect Brain HAL
Inbreeding (b) 0.420
Parent of origin (m) 0.435
Symmetric epistasis (v) 0.450
Asymmetric epistasis (w) 0.416
Sex × additive (aS) 0.434
Sex × inbreeding (bS) 0.432
Sex × parent of origin (mS) 0.432
Sex × symmetric epistasis (vS) 0.425
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Figure 4.5: Highest posterior density intervals of diallel effects for Brain HAL
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4.2.4 Straw plot of single-strain effects
Figure 4.6: Straw plot of single-strain effects and predicted homozygotes for Brain HAL
4.2.5 Variance Projection
Table 4.5: diallel variance projection (VarP) for Brain HAL (posterior medians and 95 percent credibility intervals)

























Sex × additive (aS)
1.03
(-0.08, 5.18)
Sex × inbreeding (bS)
0.07
(-0.05, 0.15)
Sex × parent of origin (mS)
0.33
(-0.04, 1.77)
Sex × symmetric epistasis (vS)
0.66
(-0.11, 4.22)
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4.2.6 Variance Projection (aggregated)
Table 4.6: Aggegrated diallel variance projection (VarP) for Brain HAL (posterior medians and 95 percent credibility intervals)
































5.1.1 Observed and predicted values
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5.1.2 Model selection MIPs
Table 5.1: Model inclusion probabilities (MIPs) for $EPSpre$
Diallel effect EPSpre
Overall inbreeding (B) 0.005
Overall sex (S) 0.055
Overall sex × inbreeding (BS) 0.005
Additive (a) 1.000
Inbreeding (b) 0.987
Parent of origin (m) 0.629
Symmetric epistasis (v) 0.999
Asymmetric epistasis (w) 0.949
Sex × additive (aS) 0.059
Sex × inbreeding (bS) 0.085
Sex × parent of origin (mS) 0.006
Sex × symmetric epistasis (vS) 0.073
Sex × asymmetric epistasis (wS) 0.025
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5.1.4 Straw plot of single-strain effects
Figure 5.3: Straw plot of single-strain effects and predicted homozygotes for $EPSpre$
5.1.5 Variance Projection


























Sex × additive (aS)
1.23
(0.14, 2.50)
Sex × inbreeding (bS)
0.35
(-0.09, 0.95)
Sex × parent of origin (mS)
0.72
(0.03, 1.66)
Sex × symmetric epistasis (vS)
1.24
(0.31, 2.48)
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5.1.6 Variance Projection (aggregated)




































Figure 5.4: $EPSpre$ observed phenotype values
5.2.2 Model selection MIPs
Table 5.4: Model inclusion probabilities (MIPs) for $EPSpre$
Diallel effect EPSpre
Inbreeding (b) 0.624
Parent of origin (m) 0.550
Symmetric epistasis (v) 0.625
Asymmetric epistasis (w) 0.604
Sex × additive (aS) 0.381
Sex × inbreeding (bS) 0.390
Sex × parent of origin (mS) 0.376
Sex × symmetric epistasis (vS) 0.395
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5.2.4 Straw plot of single-strain effects
Figure 5.6: Straw plot of single-strain effects and predicted homozygotes for $EPSpre$
5.2.5 Variance Projection


























Sex × additive (aS)
1.15
(0.18, 2.37)
Sex × inbreeding (bS)
0.33
(-0.09, 0.94)
Sex × parent of origin (mS)
0.67
(-0.00, 1.52)
Sex × symmetric epistasis (vS)
1.20
(0.25, 2.36)















Crowley, Kim, Lenarcic, et al
August 3, 2013
5.2.6 Variance Projection (aggregated)
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5.3 Gain score for placebo-treated
5.3.1 Observed and predicted values
Figure 5.7: $EPSgain placebo$ observed and predicted phenotype values
5.3.2 Model selection MIPs
Table 5.7: Model inclusion probabilities (MIPs) for $EPSgain placebo$
Diallel effect EPSgainplacebo
Overall inbreeding (B) 0.018
Overall sex (S) 0.007
Overall sex × inbreeding (BS) 0.031
Additive (a) 0.015
Inbreeding (b) 0.342
Parent of origin (m) 0.020
Symmetric epistasis (v) 0.164
Asymmetric epistasis (w) 0.061
Sex × additive (aS) 0.069
Sex × inbreeding (bS) 0.145
Sex × parent of origin (mS) 0.066
Sex × symmetric epistasis (vS) 0.108
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5.3.4 Straw plot of single-strain effects
Figure 5.9: Straw plot of single-strain effects and predicted homozygotes for $EPSgain placebo$
5.3.5 Variance Projection


























Sex × additive (aS)
3.38
(0.18, 7.99)
Sex × inbreeding (bS)
1.00
(-0.26, 3.63)
Sex × parent of origin (mS)
3.01
(0.07, 7.09)
Sex × symmetric epistasis (vS)
3.40
(0.13, 8.65)
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5.3.6 Variance Projection (aggregated)
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5.4 Gain score for placebo-treated, weight-adjusted
5.4.1 Observed values
Figure 5.10: $EPSgain placebo$ observed phenotype values
5.4.2 Model selection MIPs
Table 5.10: Model inclusion probabilities (MIPs) for $EPSgain placebo$
Diallel effect EPSgainplacebo
Inbreeding (b) 0.455
Parent of origin (m) 0.382
Symmetric epistasis (v) 0.412
Asymmetric epistasis (w) 0.393
Sex × additive (aS) 0.389
Sex × inbreeding (bS) 0.415
Sex × parent of origin (mS) 0.395
Sex × symmetric epistasis (vS) 0.407
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5.4.4 Straw plot of single-strain effects
Figure 5.12: Straw plot of single-strain effects and predicted homozygotes for $EPSgain placebo$
5.4.5 Variance Projection


























Sex × additive (aS)
3.35
(0.14, 8.26)
Sex × inbreeding (bS)
1.16
(-0.24, 4.32)
Sex × parent of origin (mS)
3.13
(0.06, 7.38)
Sex × symmetric epistasis (vS)
3.20
(0.20, 8.34)















Crowley, Kim, Lenarcic, et al
August 3, 2013
5.4.6 Variance Projection (aggregated)
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5.5 Gain score for drug-treated
5.5.1 Observed and predicted values
Figure 5.13: $EPSgain drug$ observed and predicted phenotype values
5.5.2 Model selection MIPs
Table 5.13: Model inclusion probabilities (MIPs) for $EPSgain drug$
Diallel effect EPSgaindrug
Overall inbreeding (B) 0.039
Overall sex (S) 0.011
Overall sex × inbreeding (BS) 0.027
Additive (a) 1.000
Inbreeding (b) 0.218
Parent of origin (m) 0.364
Symmetric epistasis (v) 0.890
Asymmetric epistasis (w) 0.998
Sex × additive (aS) 0.239
Sex × inbreeding (bS) 0.230
Sex × parent of origin (mS) 0.169
Sex × symmetric epistasis (vS) 0.306
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5.5.4 Straw plot of single-strain effects
Figure 5.15: Straw plot of single-strain effects and predicted homozygotes for $EPSgain drug$
5.5.5 Variance Projection


























Sex × additive (aS)
1.18
(-0.05, 3.02)
Sex × inbreeding (bS)
0.28
(-0.10, 1.02)
Sex × parent of origin (mS)
1.06
(-0.13, 2.80)
Sex × symmetric epistasis (vS)
1.37
(0.04, 3.70)
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5.5.6 Variance Projection (aggregated)
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5.6 Gain score for drug-treated, weight-adjusted
5.6.1 Observed values
Figure 5.16: $EPSgain placebo$ observed phenotype values
5.6.2 Model selection MIPs
Table 5.16: Model inclusion probabilities (MIPs) for $EPSgain placebo$
Diallel effect EPSgainplacebo
Inbreeding (b) 0.455
Parent of origin (m) 0.382
Symmetric epistasis (v) 0.412
Asymmetric epistasis (w) 0.393
Sex × additive (aS) 0.389
Sex × inbreeding (bS) 0.415
Sex × parent of origin (mS) 0.395
Sex × symmetric epistasis (vS) 0.407
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5.6.4 Straw plot of single-strain effects
Figure 5.18: Straw plot of single-strain effects and predicted homozygotes for $EPSgain placebo$
5.6.5 Variance Projection


























Sex × additive (aS)
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Sex × inbreeding (bS)
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5.6.6 Variance Projection (aggregated)
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5.7 Drug response, MP estimate
5.7.1 Observed and predicted values
Figure 5.19: $EPStreat MP$ observed and predicted phenotype values
5.7.2 Model selection MIPs
Table 5.19: Model inclusion probabilities (MIPs) for $EPStreat MP$
Diallel effect EPStreatMP
Overall inbreeding (B) 0.021
Overall sex (S) 0.021
Overall sex × inbreeding (BS) 0.049
Additive (a) 1.000
Inbreeding (b) 0.231
Parent of origin (m) 0.711
Symmetric epistasis (v) 0.352
Asymmetric epistasis (w) 0.647
Sex × additive (aS) 0.123
Sex × inbreeding (bS) 0.215
Sex × parent of origin (mS) 0.140
Sex × symmetric epistasis (vS) 0.185
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5.7.4 Straw plot of single-strain effects
Figure 5.21: Straw plot of single-strain effects and predicted homozygotes for $EPStreat MP$
5.7.5 Treatment Response Variance Projection


























Sex × additive (aS)
1.15
(-0.06, 3.14)
Sex × inbreeding (bS)
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Sex × parent of origin (mS)
1.28
(-0.07, 3.42)
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5.7.6 Treatment Response Variance Projection (aggregated)
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5.8 Drug response, DoM estimate
5.8.1 Observed values
Figure 5.22: $EPStreat DoM$ observed phenotype values
5.8.2 Model selection MIPs
Table 5.22: Model inclusion probabilities (MIPs) for $EPStreat DoM$
Diallel effect EPStreatDoM
Overall inbreeding (B) 0.039
Overall sex (S) 0.011
Overall sex × inbreeding (BS) 0.031
Additive (a) 1.000
Inbreeding (b) 0.342
Parent of origin (m) 0.364
Symmetric epistasis (v) 0.890
Asymmetric epistasis (w) 0.998
Sex × additive (aS) 0.239
Sex × inbreeding (bS) 0.230
Sex × parent of origin (mS) 0.169
Sex × symmetric epistasis (vS) 0.306
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5.8.4 Straw plot of single-strain effects
Figure 5.24: Straw plot of single-strain effects and predicted homozygotes for $EPStreat DoM$
5.8.5 Treatment Response Variance Projection


























Sex × additive (aS)
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Sex × inbreeding (bS)
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Sex × parent of origin (mS)
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5.8.6 Treatment Response Variance Projection (aggregated)
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5.9 Drug response, DoM estimate, weight-adjusted
5.9.1 Observed values
Figure 5.25: $EPStreat DoM$ observed phenotype values
5.9.2 Model selection MIPs
Table 5.25: Model inclusion probabilities (MIPs) for $EPStreat DoM$
Diallel effect EPStreatDoM
Inbreeding (b) 0.455
Parent of origin (m) 0.466
Symmetric epistasis (v) 0.617
Asymmetric epistasis (w) 0.625
Sex × additive (aS) 0.415
Sex × inbreeding (bS) 0.427
Sex × parent of origin (mS) 0.408
Sex × symmetric epistasis (vS) 0.458
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5.9.4 Straw plot of single-strain effects
Figure 5.27: Straw plot of single-strain effects and predicted homozygotes for $EPStreat DoM$
5.9.5 Treatment Response Variance Projection


























Sex × additive (aS)
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5.9.6 Treatment Response Variance Projection (aggregated)


































6.1.1 Observed and predicted values
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6.1.2 Model selection MIPs
Table 6.1: Model inclusion probabilities (MIPs) for $OFApre$
Diallel effect OFApre
Overall inbreeding (B) 0.809
Overall sex (S) 0.999
Overall sex × inbreeding (BS) 0.068
Additive (a) 1.000
Inbreeding (b) 0.998
Parent of origin (m) 0.777
Symmetric epistasis (v) 1.000
Asymmetric epistasis (w) 0.999
Sex × additive (aS) 0.431
Sex × inbreeding (bS) 0.255
Sex × parent of origin (mS) 0.316
Sex × symmetric epistasis (vS) 0.316
Sex × asymmetric epistasis (wS) 0.276
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6.1.4 Straw plot of single-strain effects
Figure 6.3: Straw plot of single-strain effects and predicted homozygotes for $OFApre$
6.1.5 Variance Projection
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6.1.6 Variance Projection (aggregated)




































Figure 6.4: $OFApre$ observed phenotype values
6.2.2 Model selection MIPs
Table 6.4: Model inclusion probabilities (MIPs) for $OFApre$
Diallel effect OFApre
Inbreeding (b) 0.624
Parent of origin (m) 0.560
Symmetric epistasis (v) 0.625
Asymmetric epistasis (w) 0.625
Sex × additive (aS) 0.468
Sex × inbreeding (bS) 0.440
Sex × parent of origin (mS) 0.444
Sex × symmetric epistasis (vS) 0.447
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6.2.4 Straw plot of single-strain effects
Figure 6.6: Straw plot of single-strain effects and predicted homozygotes for $OFApre$
6.2.5 Variance Projection
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6.2.6 Variance Projection (aggregated)
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6.3 Gain score for placebo-treated
6.3.1 Observed and predicted values
Figure 6.7: $OFAgain placebo$ observed and predicted phenotype values
6.3.2 Model selection MIPs
Table 6.7: Model inclusion probabilities (MIPs) for $OFAgain placebo$
Diallel effect OFAgainplacebo
Overall inbreeding (B) 0.987
Overall sex (S) 0.097
Overall sex × inbreeding (BS) 0.085
Additive (a) 0.361
Inbreeding (b) 0.939
Parent of origin (m) 0.710
Symmetric epistasis (v) 0.896
Asymmetric epistasis (w) 0.271
Sex × additive (aS) 0.213
Sex × inbreeding (bS) 0.218
Sex × parent of origin (mS) 0.184
Sex × symmetric epistasis (vS) 0.207
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6.3.4 Straw plot of single-strain effects
Figure 6.9: Straw plot of single-strain effects and predicted homozygotes for $OFAgain placebo$
6.3.5 Variance Projection
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6.3.6 Variance Projection (aggregated)
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6.4 Gain score for placebo-treated, weight-adjusted
6.4.1 Observed values
Figure 6.10: $OFAgain placebo$ observed phenotype values
6.4.2 Model selection MIPs
Table 6.10: Model inclusion probabilities (MIPs) for $OFAgain placebo$
Diallel effect OFAgainplacebo
Inbreeding (b) 0.611
Parent of origin (m) 0.541
Symmetric epistasis (v) 0.612
Asymmetric epistasis (w) 0.427
Sex × additive (aS) 0.424
Sex × inbreeding (bS) 0.434
Sex × parent of origin (mS) 0.422
Sex × symmetric epistasis (vS) 0.435
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6.4.4 Straw plot of single-strain effects
Figure 6.12: Straw plot of single-strain effects and predicted homozygotes for $OFAgain placebo$
6.4.5 Variance Projection
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6.4.6 Variance Projection (aggregated)
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6.5 Gain score for drug-treated
6.5.1 Observed and predicted values
Figure 6.13: $OFAgain drug$ observed and predicted phenotype values
6.5.2 Model selection MIPs
Table 6.13: Model inclusion probabilities (MIPs) for $OFAgain drug$
Diallel effect OFAgaindrug
Overall inbreeding (B) 1.000
Overall sex (S) 0.202
Overall sex × inbreeding (BS) 0.755
Additive (a) 1.000
Inbreeding (b) 0.257
Parent of origin (m) 0.198
Symmetric epistasis (v) 0.223
Asymmetric epistasis (w) 0.175
Sex × additive (aS) 0.235
Sex × inbreeding (bS) 0.201
Sex × parent of origin (mS) 0.186
Sex × symmetric epistasis (vS) 0.202
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6.5.4 Straw plot of single-strain effects
Figure 6.15: Straw plot of single-strain effects and predicted homozygotes for $OFAgain drug$
6.5.5 Variance Projection
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6.5.6 Variance Projection (aggregated)
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6.6 Gain score for drug-treated, weight-adjusted
6.6.1 Observed values
Figure 6.16: $OFAgain placebo$ observed phenotype values
6.6.2 Model selection MIPs
Table 6.16: Model inclusion probabilities (MIPs) for $OFAgain placebo$
Diallel effect OFAgainplacebo
Inbreeding (b) 0.611
Parent of origin (m) 0.541
Symmetric epistasis (v) 0.612
Asymmetric epistasis (w) 0.427
Sex × additive (aS) 0.424
Sex × inbreeding (bS) 0.434
Sex × parent of origin (mS) 0.422
Sex × symmetric epistasis (vS) 0.435
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6.6.4 Straw plot of single-strain effects
Figure 6.18: Straw plot of single-strain effects and predicted homozygotes for $OFAgain placebo$
6.6.5 Variance Projection
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6.6.6 Variance Projection (aggregated)
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6.7 Drug response, MP estimate
6.7.1 Observed and predicted values
Figure 6.19: $OFAtreat MP$ observed and predicted phenotype values
6.7.2 Model selection MIPs
Table 6.19: Model inclusion probabilities (MIPs) for $OFAtreat MP$
Diallel effect OFAtreatMP
Overall inbreeding (B) 0.144
Overall sex (S) 0.085
Overall sex × inbreeding (BS) 0.563
Additive (a) 0.510
Inbreeding (b) 0.751
Parent of origin (m) 0.187
Symmetric epistasis (v) 0.231
Asymmetric epistasis (w) 0.198
Sex × additive (aS) 0.224
Sex × inbreeding (bS) 0.213
Sex × parent of origin (mS) 0.203
Sex × symmetric epistasis (vS) 0.212
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6.7.4 Straw plot of single-strain effects
Figure 6.21: Straw plot of single-strain effects and predicted homozygotes for $OFAtreat MP$
6.7.5 Treatment Response Variance Projection
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6.7.6 Treatment Response Variance Projection (aggregated)
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6.8 Drug response, DoM estimate
6.8.1 Observed values
Figure 6.22: $OFAtreat DoM$ observed phenotype values
6.8.2 Model selection MIPs
Table 6.22: Model inclusion probabilities (MIPs) for $OFAtreat DoM$
Diallel effect OFAtreatDoM
Overall inbreeding (B) 1.000
Overall sex (S) 0.202
Overall sex × inbreeding (BS) 0.755
Additive (a) 1.000
Inbreeding (b) 0.939
Parent of origin (m) 0.710
Symmetric epistasis (v) 0.896
Asymmetric epistasis (w) 0.271
Sex × additive (aS) 0.235
Sex × inbreeding (bS) 0.218
Sex × parent of origin (mS) 0.186
Sex × symmetric epistasis (vS) 0.207
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6.8.4 Straw plot of single-strain effects
Figure 6.24: Straw plot of single-strain effects and predicted homozygotes for $OFAtreat DoM$
6.8.5 Treatment Response Variance Projection
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6.8.6 Treatment Response Variance Projection (aggregated)
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6.9 Drug response, DoM estimate, weight-adjusted
6.9.1 Observed values
Figure 6.25: $OFAtreat DoM$ observed phenotype values
6.9.2 Model selection MIPs
Table 6.25: Model inclusion probabilities (MIPs) for $OFAtreat DoM$
Diallel effect OFAtreatDoM
Inbreeding (b) 0.611
Parent of origin (m) 0.541
Symmetric epistasis (v) 0.612
Asymmetric epistasis (w) 0.428
Sex × additive (aS) 0.424
Sex × inbreeding (bS) 0.434
Sex × parent of origin (mS) 0.429
Sex × symmetric epistasis (vS) 0.435
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6.9.4 Straw plot of single-strain effects
Figure 6.27: Straw plot of single-strain effects and predicted homozygotes for $OFAtreat DoM$
6.9.5 Treatment Response Variance Projection
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6.9.6 Treatment Response Variance Projection (aggregated)


































7.1.1 Observed and predicted values
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7.1.2 Model selection MIPs
Table 7.1: Model inclusion probabilities (MIPs) for $PPIpre$
Diallel effect PPIpre
Overall inbreeding (B) 0.002
Overall sex (S) 0.999
Overall sex × inbreeding (BS) 0.005
Additive (a) 1.000
Inbreeding (b) 0.116
Parent of origin (m) 0.003
Symmetric epistasis (v) 1.000
Asymmetric epistasis (w) 0.016
Sex × additive (aS) 0.032
Sex × inbreeding (bS) 0.070
Sex × parent of origin (mS) 0.000
Sex × symmetric epistasis (vS) 0.083
Sex × asymmetric epistasis (wS) 0.001
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7.1.4 Straw plot of single-strain effects
Figure 7.3: Straw plot of single-strain effects and predicted homozygotes for $PPIpre$
7.1.5 Variance Projection
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7.1.6 Variance Projection (aggregated)




































Figure 7.4: $PPIpre$ observed phenotype values
7.2.2 Model selection MIPs
Table 7.4: Model inclusion probabilities (MIPs) for $PPIpre$
Diallel effect PPIpre
Inbreeding (b) 0.400
Parent of origin (m) 0.376
Symmetric epistasis (v) 0.625
Asymmetric epistasis (w) 0.377
Sex × additive (aS) 0.381
Sex × inbreeding (bS) 0.398
Sex × parent of origin (mS) 0.375
Sex × symmetric epistasis (vS) 0.389
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7.2.4 Straw plot of single-strain effects
Figure 7.6: Straw plot of single-strain effects and predicted homozygotes for $PPIpre$
7.2.5 Variance Projection
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7.2.6 Variance Projection (aggregated)
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7.3 Gain score for placebo-treated
7.3.1 Observed and predicted values
Figure 7.7: $PPIgain placebo$ observed and predicted phenotype values
7.3.2 Model selection MIPs
Table 7.7: Model inclusion probabilities (MIPs) for $PPIgain placebo$
Diallel effect PPIgainplacebo
Overall inbreeding (B) 0.013
Overall sex (S) 0.014
Overall sex × inbreeding (BS) 0.506
Additive (a) 0.030
Inbreeding (b) 0.144
Parent of origin (m) 0.011
Symmetric epistasis (v) 0.156
Asymmetric epistasis (w) 0.112
Sex × additive (aS) 0.090
Sex × inbreeding (bS) 0.318
Sex × parent of origin (mS) 0.051
Sex × symmetric epistasis (vS) 0.135
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7.3.4 Straw plot of single-strain effects
Figure 7.9: Straw plot of single-strain effects and predicted homozygotes for $PPIgain placebo$
7.3.5 Variance Projection
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7.3.6 Variance Projection (aggregated)
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7.4 Gain score for placebo-treated, weight-adjusted
7.4.1 Observed values
Figure 7.10: $PPIgain placebo$ observed phenotype values
7.4.2 Model selection MIPs
Table 7.10: Model inclusion probabilities (MIPs) for $PPIgain placebo$
Diallel effect PPIgainplacebo
Inbreeding (b) 0.411
Parent of origin (m) 0.378
Symmetric epistasis (v) 0.412
Asymmetric epistasis (w) 0.406
Sex × additive (aS) 0.397
Sex × inbreeding (bS) 0.455
Sex × parent of origin (mS) 0.386
Sex × symmetric epistasis (vS) 0.418
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7.4.4 Straw plot of single-strain effects
Figure 7.12: Straw plot of single-strain effects and predicted homozygotes for $PPIgain placebo$
7.4.5 Variance Projection
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7.4.6 Variance Projection (aggregated)
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7.5 Gain score for drug-treated
7.5.1 Observed and predicted values
Figure 7.13: $PPIgain drug$ observed and predicted phenotype values
7.5.2 Model selection MIPs
Table 7.13: Model inclusion probabilities (MIPs) for $PPIgain drug$
Diallel effect PPIgaindrug
Overall inbreeding (B) 0.015
Overall sex (S) 0.027
Overall sex × inbreeding (BS) 0.029
Additive (a) 0.501
Inbreeding (b) 0.263
Parent of origin (m) 0.129
Symmetric epistasis (v) 0.560
Asymmetric epistasis (w) 0.917
Sex × additive (aS) 0.210
Sex × inbreeding (bS) 0.199
Sex × parent of origin (mS) 0.094
Sex × symmetric epistasis (vS) 0.215
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7.5.4 Straw plot of single-strain effects
Figure 7.15: Straw plot of single-strain effects and predicted homozygotes for $PPIgain drug$
7.5.5 Variance Projection
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7.5.6 Variance Projection (aggregated)
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7.6 Gain score for drug-treated, weight-adjusted
7.6.1 Observed values
Figure 7.16: $PPIgain placebo$ observed phenotype values
7.6.2 Model selection MIPs
Table 7.16: Model inclusion probabilities (MIPs) for $PPIgain placebo$
Diallel effect PPIgainplacebo
Inbreeding (b) 0.411
Parent of origin (m) 0.378
Symmetric epistasis (v) 0.412
Asymmetric epistasis (w) 0.406
Sex × additive (aS) 0.397
Sex × inbreeding (bS) 0.455
Sex × parent of origin (mS) 0.386
Sex × symmetric epistasis (vS) 0.418
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7.6.4 Straw plot of single-strain effects
Figure 7.18: Straw plot of single-strain effects and predicted homozygotes for $PPIgain placebo$
7.6.5 Variance Projection
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7.6.6 Variance Projection (aggregated)
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7.7 Drug response, MP estimate
7.7.1 Observed and predicted values
Figure 7.19: $PPItreat MP$ observed and predicted phenotype values
7.7.2 Model selection MIPs
Table 7.19: Model inclusion probabilities (MIPs) for $PPItreat MP$
Diallel effect PPItreatMP
Overall inbreeding (B) 0.024
Overall sex (S) 0.012
Overall sex × inbreeding (BS) 0.094
Additive (a) 0.284
Inbreeding (b) 0.277
Parent of origin (m) 0.115
Symmetric epistasis (v) 0.451
Asymmetric epistasis (w) 0.506
Sex × additive (aS) 0.253
Sex × inbreeding (bS) 0.293
Sex × parent of origin (mS) 0.112
Sex × symmetric epistasis (vS) 0.148
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7.7.4 Straw plot of single-strain effects
Figure 7.21: Straw plot of single-strain effects and predicted homozygotes for $PPItreat MP$
7.7.5 Treatment Response Variance Projection
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7.7.6 Treatment Response Variance Projection (aggregated)
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7.8 Drug response, DoM estimate
7.8.1 Observed values
Figure 7.22: $PPItreat DoM$ observed phenotype values
7.8.2 Model selection MIPs
Table 7.22: Model inclusion probabilities (MIPs) for $PPItreat DoM$
Diallel effect PPItreatDoM
Overall inbreeding (B) 0.015
Overall sex (S) 0.027
Overall sex × inbreeding (BS) 0.506
Additive (a) 0.501
Inbreeding (b) 0.263
Parent of origin (m) 0.129
Symmetric epistasis (v) 0.560
Asymmetric epistasis (w) 0.917
Sex × additive (aS) 0.210
Sex × inbreeding (bS) 0.318
Sex × parent of origin (mS) 0.094
Sex × symmetric epistasis (vS) 0.215
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7.8.4 Straw plot of single-strain effects
Figure 7.24: Straw plot of single-strain effects and predicted homozygotes for $PPItreat DoM$
7.8.5 Treatment Response Variance Projection
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7.8.6 Treatment Response Variance Projection (aggregated)
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7.9 Drug response, DoM estimate, weight-adjusted
7.9.1 Observed values
Figure 7.25: $PPItreat DoM$ observed phenotype values
7.9.2 Model selection MIPs
Table 7.25: Model inclusion probabilities (MIPs) for $PPItreat DoM$
Diallel effect PPItreatDoM
Inbreeding (b) 0.448
Parent of origin (m) 0.404
Symmetric epistasis (v) 0.531
Asymmetric epistasis (w) 0.607
Sex × additive (aS) 0.428
Sex × inbreeding (bS) 0.455
Sex × parent of origin (mS) 0.398
Sex × symmetric epistasis (vS) 0.428
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7.9.4 Straw plot of single-strain effects
Figure 7.27: Straw plot of single-strain effects and predicted homozygotes for $PPItreat DoM$
7.9.5 Treatment Response Variance Projection
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7.9.6 Treatment Response Variance Projection (aggregated)


































8.1.1 Observed and predicted values
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8.1.2 Model selection MIPs
Table 8.1: Model inclusion probabilities (MIPs) for $VCMpre$
Diallel effect VCMpre
Overall inbreeding (B) 0.005
Overall sex (S) 0.009
Overall sex × inbreeding (BS) 0.035
Additive (a) 0.940
Inbreeding (b) 0.257
Parent of origin (m) 0.017
Symmetric epistasis (v) 0.832
Asymmetric epistasis (w) 0.055
Sex × additive (aS) 0.097
Sex × inbreeding (bS) 0.134
Sex × parent of origin (mS) 0.011
Sex × symmetric epistasis (vS) 0.032
Sex × asymmetric epistasis (wS) 0.042
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8.1.4 Straw plot of single-strain effects
Figure 8.3: Straw plot of single-strain effects and predicted homozygotes for $VCMpre$
8.1.5 Variance Projection
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8.1.6 Variance Projection (aggregated)




































Figure 8.4: $VCMpre$ observed phenotype values
8.2.2 Model selection MIPs
Table 8.4: Model inclusion probabilities (MIPs) for $VCMpre$
Diallel effect VCMpre
Inbreeding (b) 0.492
Parent of origin (m) 0.382
Symmetric epistasis (v) 0.619
Asymmetric epistasis (w) 0.396
Sex × additive (aS) 0.394
Sex × inbreeding (bS) 0.403
Sex × parent of origin (mS) 0.379
Sex × symmetric epistasis (vS) 0.382
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8.2.4 Straw plot of single-strain effects
Figure 8.6: Straw plot of single-strain effects and predicted homozygotes for $VCMpre$
8.2.5 Variance Projection
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8.2.6 Variance Projection (aggregated)
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8.3 Gain score for placebo-treated
8.3.1 Observed and predicted values
Figure 8.7: $VCMgain placebo$ observed and predicted phenotype values
8.3.2 Model selection MIPs
Table 8.7: Model inclusion probabilities (MIPs) for $VCMgain placebo$
Diallel effect VCMgainplacebo
Overall inbreeding (B) 0.016
Overall sex (S) 0.215
Overall sex × inbreeding (BS) 0.115
Additive (a) 0.896
Inbreeding (b) 0.732
Parent of origin (m) 0.038
Symmetric epistasis (v) 0.208
Asymmetric epistasis (w) 0.114
Sex × additive (aS) 0.400
Sex × inbreeding (bS) 0.180
Sex × parent of origin (mS) 0.050
Sex × symmetric epistasis (vS) 0.319




Crowley, Kim, Lenarcic, et al
August 3, 2013






























−3 −2 −1 0 1 2 3











































































































−3 −2 −1 0 1 2 3
































































































































−3 −2 −1 0 1 2 3














































































































−3 −2 −1 0 1 2 3





































































































Crowley, Kim, Lenarcic, et al
August 3, 2013
8.3.4 Straw plot of single-strain effects
Figure 8.9: Straw plot of single-strain effects and predicted homozygotes for $VCMgain placebo$
8.3.5 Variance Projection
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8.3.6 Variance Projection (aggregated)
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8.4 Gain score for placebo-treated, weight-adjusted
8.4.1 Observed values
Figure 8.10: $VCMgain placebo$ observed phenotype values
8.4.2 Model selection MIPs
Table 8.10: Model inclusion probabilities (MIPs) for $VCMgain placebo$
Diallel effect VCMgainplacebo
Inbreeding (b) 0.607
Parent of origin (m) 0.386
Symmetric epistasis (v) 0.599
Asymmetric epistasis (w) 0.413
Sex × additive (aS) 0.408
Sex × inbreeding (bS) 0.428
Sex × parent of origin (mS) 0.385
Sex × symmetric epistasis (vS) 0.413
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8.4.4 Straw plot of single-strain effects
Figure 8.12: Straw plot of single-strain effects and predicted homozygotes for $VCMgain placebo$
8.4.5 Variance Projection
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8.4.6 Variance Projection (aggregated)
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8.5 Gain score for drug-treated
8.5.1 Observed and predicted values
Figure 8.13: $VCMgain drug$ observed and predicted phenotype values
8.5.2 Model selection MIPs
Table 8.13: Model inclusion probabilities (MIPs) for $VCMgain drug$
Diallel effect VCMgaindrug
Overall inbreeding (B) 0.754
Overall sex (S) 0.011
Overall sex × inbreeding (BS) 0.489
Additive (a) 0.072
Inbreeding (b) 0.765
Parent of origin (m) 0.181
Symmetric epistasis (v) 0.532
Asymmetric epistasis (w) 0.486
Sex × additive (aS) 0.461
Sex × inbreeding (bS) 0.887
Sex × parent of origin (mS) 0.187
Sex × symmetric epistasis (vS) 0.477
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8.5.4 Straw plot of single-strain effects
Figure 8.15: Straw plot of single-strain effects and predicted homozygotes for $VCMgain drug$
8.5.5 Variance Projection
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8.5.6 Variance Projection (aggregated)
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8.6 Gain score for drug-treated, weight-adjusted
8.6.1 Observed values
Figure 8.16: $VCMgain placebo$ observed phenotype values
8.6.2 Model selection MIPs
Table 8.16: Model inclusion probabilities (MIPs) for $VCMgain placebo$
Diallel effect VCMgainplacebo
Inbreeding (b) 0.607
Parent of origin (m) 0.386
Symmetric epistasis (v) 0.599
Asymmetric epistasis (w) 0.413
Sex × additive (aS) 0.408
Sex × inbreeding (bS) 0.428
Sex × parent of origin (mS) 0.385
Sex × symmetric epistasis (vS) 0.413
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8.6.4 Straw plot of single-strain effects
Figure 8.18: Straw plot of single-strain effects and predicted homozygotes for $VCMgain placebo$
8.6.5 Variance Projection
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8.6.6 Variance Projection (aggregated)
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8.7 Drug response, MP estimate
8.7.1 Observed and predicted values
Figure 8.19: $VCMtreat MP$ observed and predicted phenotype values
8.7.2 Model selection MIPs
Table 8.19: Model inclusion probabilities (MIPs) for $VCMtreat MP$
Diallel effect VCMtreatMP
Overall inbreeding (B) 0.048
Overall sex (S) 0.013
Overall sex × inbreeding (BS) 0.075
Additive (a) 0.064
Inbreeding (b) 0.362
Parent of origin (m) 0.093
Symmetric epistasis (v) 0.119
Asymmetric epistasis (w) 0.246
Sex × additive (aS) 0.122
Sex × inbreeding (bS) 0.201
Sex × parent of origin (mS) 0.173
Sex × symmetric epistasis (vS) 0.142
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8.7.4 Straw plot of single-strain effects
Figure 8.21: Straw plot of single-strain effects and predicted homozygotes for $VCMtreat MP$
8.7.5 Treatment Response Variance Projection


























Sex × additive (aS)
3.36
(-0.04, 9.16)
Sex × inbreeding (bS)
0.85
(-0.24, 3.29)
Sex × parent of origin (mS)
5.74
(0.03, 15.01)
Sex × symmetric epistasis (vS)
3.00
(-0.06, 8.55)












Crowley, Kim, Lenarcic, et al
August 3, 2013
8.7.6 Treatment Response Variance Projection (aggregated)

































Crowley, Kim, Lenarcic, et al
August 3, 2013
8.8 Drug response, DoM estimate
8.8.1 Observed values
Figure 8.22: $VCMtreat DoM$ observed phenotype values
8.8.2 Model selection MIPs
Table 8.22: Model inclusion probabilities (MIPs) for $VCMtreat DoM$
Diallel effect VCMtreatDoM
Overall inbreeding (B) 0.754
Overall sex (S) 0.215
Overall sex × inbreeding (BS) 0.489
Additive (a) 0.896
Inbreeding (b) 0.765
Parent of origin (m) 0.181
Symmetric epistasis (v) 0.532
Asymmetric epistasis (w) 0.486
Sex × additive (aS) 0.461
Sex × inbreeding (bS) 0.887
Sex × parent of origin (mS) 0.187
Sex × symmetric epistasis (vS) 0.477
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8.8.4 Straw plot of single-strain effects
Figure 8.24: Straw plot of single-strain effects and predicted homozygotes for $VCMtreat DoM$
8.8.5 Treatment Response Variance Projection
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8.8.6 Treatment Response Variance Projection (aggregated)
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8.9 Drug response, DoM estimate, weight-adjusted
8.9.1 Observed values
Figure 8.25: $VCMtreat DoM$ observed phenotype values
8.9.2 Model selection MIPs
Table 8.25: Model inclusion probabilities (MIPs) for $VCMtreat DoM$
Diallel effect VCMtreatDoM
Inbreeding (b) 0.607
Parent of origin (m) 0.546
Symmetric epistasis (v) 0.599
Asymmetric epistasis (w) 0.523
Sex × additive (aS) 0.421
Sex × inbreeding (bS) 0.437
Sex × parent of origin (mS) 0.497
Sex × symmetric epistasis (vS) 0.516
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8.9.4 Straw plot of single-strain effects
Figure 8.27: Straw plot of single-strain effects and predicted homozygotes for $VCMtreat DoM$
8.9.5 Treatment Response Variance Projection
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8.9.6 Treatment Response Variance Projection (aggregated)





































Available for download as an Excel file at http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.113.156901/-/DC1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
